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Course Portfolio for BIOS 412/812 Human Genetics: Synthetic Review Paper
Abstract: This portfolio focuses on Human Genetics, an upper-division course taken
primarily by biology majors to fulfill elective credit in their degree. This course studies
the genetic basis for human variation, with the goal of placing this variation in the context
of human evolutionary history and the consequences of this variation for medical
understanding and treatments. In Human Genetics, students complete an original
synthetic research paper on a human genetic disorder. Through writing this paper,
students are expected to learn how to navigate electronic databases and online resources
on human genetic diseases, and to read and synthesize the primary scientific literature.
This portfolio describes the teaching methods used to guide students through this process.
The information and concepts to be taught in Human Genetics are expected to be useful
for students going on to do research in a biological field, for those intending to pursue
medical and health-related professions, and in general in producing informed and critical
citizens who are empowered to make scientifically sound decisions.
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1. Objectives of the Portfolio
The objective of this Peer Review Course Portfolio is to develop and document the
curriculum for BIOS412/812, Human Genetics. This course has been historically taught
by a faculty member who is retiring, and so I took over this responsibility and taught the
class for the first time in the Spring Semester of 2016.
One goal of this portfolio was to make the learning objectives for this course explicit and
design performance-based assessments. Through the workshops and retreats in the Peer
Review of Teaching Program, these goals were developed and ultimately incorporated as
a list of specific learning objectives (included in the course syllabus) and just-in-timeteaching (JiTT) weekly assignments.
Because BIOS412 is an ACE10 class, it is expected provide the students with an
educational experience that both teaches and assesses information collection, synthesis,
interpretation, presentation, and reflection. Thus, a second goal of this portfolio was to
develop a research paper project that fulfills these goals. Documents provided to the
students to guide their research and paper-writing and examples of student papers are
included in the appendices. I used this portfolio to help me develop this new (to me)
course, and will include it as documentation of teaching in my promotion and tenure
packages.
2. Description of the Course
Human Genetics focuses on advanced concepts in genetics, with an emphasis on human
biology and applications of this knowledge to medical diagnosis and treatment. This
includes mechanisms of inheritance, the nature of genetic variation, how this variation is
expressed, and how this variation exists in populations and over evolutionary time.
General Genetics (BIOS-206) is a prerequisite for Human Genetics; it is therefore
assumed that students will enter the class at least familiar with the molecular and cellular
basis for biological inheritance, mechanisms and control of gene expression, the basic
structure of the human genome, and the segregation of alleles in populations.
Human Genetics is designated as an ACE10 course. To fulfill the ACE10 learning
outcome ("generate a creative or scholarly product that requires broad knowledge,
appropriate technical proficiency, information collection, synthesis, interpretation,
presentation, and reflection") students write a synthetic review paper on a human genetic
disease over the course of the semester.
The major learning objectives in Human Genetics include (see Appendix A for syllabus):
1) understand the current, state-of-the-art methods used to identify genetic variation
in humans and the approaches used to connect genetic variation to phenotypic
variation, particularly disease phenotypes;

2) understand how human genetic variation informs our understanding of disease
and guides and constrains health care decisions
3) develop the critical skills required to comprehend, interpret, and critique the
primary scientific literature, with the ultimate goal of empowering students to
independently approach the scientific literature
4) synthesize a body of primary scientific literature on a human genetic disease and
write a review of the disease, describing its genetic underpinnings, its phenotypic
outcomes, and current and future approaches for diagnosis and treatment.
Student learning of these course goals was assessed using weekly short answer problem
sets based around the textbook or assigned reading; three midterm exams; and a research
paper synthesizing the scientific literature on a human genetic disorder.
In the spring semester of 2016, Human Genetics had an enrollment of 22 students in the
undergraduate section (BIOS-412) and one student in the graduate section (BIOS-812).
Of the 22 students enrolled in BIOS-412, 15 were seniors, five were juniors, and two
were graduate students. Majors included biological sciences (15 students), psychology
(1), forestry (1), microbiology (1), biochemistry (1) and plant biology (1).
3. Teaching methods
Classroom instruction and assignments: The primary mode of in-class instruction in
Human Genetics was canonical lecture. I utilized both the white-board and projected
presentations - concepts and details were loosely transcribed from prepared notes on to
the white board, while the presentation slides were mainly used to provide the students
with figures and tables from the textbook or primary literature. I wrote on the board,
rather than presenting the students with pre-written text on slides, to slow down my
presentation of the material and provide students time to take their own notes and
assimilate the material.
At least once during most classes I presented the students with a multiple-choice question
and solicited student answers via clickers. If a majority of the answers were incorrect,
the students were given the opportunity to discuss the question amongst themselves and
then I posed the question again. In almost every case the class converged on the correct
answer. After presenting the correct answer, I asked students to explain what exactly was
wrong with the incorrect answers. Often the question was posed at the very beginning of
class, as a way of focusing the students' attention and setting the atmosphere for the rest
of the class period.
Outside of class, the students were expected to read the textbook (Genetics and Genomics
in Medicine, Strachan et al. 2015) and papers from the primary scientific literature. They
were also required to complete short weekly assignments through Blackboard based on
the assigned reading. These assignments consisted of 3-5 short-answer questions, and

were assigned at the end of the week and due Monday at 11:00 (24 hours prior to class on
Tuesday). The assignments were then graded before class on Tuesday and the students'
answers were used to guide both the lecture topics and in-class questions (Just-in-TimeTeaching). Frequently the in-class question would repeat or re-state the assigned
question that seemed to provide the students with the most difficulty. Students were
given full credit on the assignments for simply providing a reasonable answer, but I
awarded more points (that did not go towards their final grades) for correct answers.
These points allowed the students to see whether their answers were correct and helped
guide their studying for the midterm exams, since some assigned questions were repeated
verbatim or only slightly modified on the exams.
Human Disease Review Paper: The major assignment outside of class was the review
paper, which constituted 20% of the final grade for the semester. The project was carried
out in stages throughout the semester, with each stage requiring an assignment to be
turned in that contributed to part of the 20% of the grade associated with the whole
project. At most stages the students got full credit for simply completing that part of the
assignment on time; but the rough draft and final draft of the paper were graded on the
merits of the work. The rationale for dividing the assignment into stages was 1) to spread
the workload out over the semester and prevent students from procrastinating; 2) allow
me to provide feedback, guidance, and course corrections throughout the process. The
stages of the research paper assignment are described below:
Stage 1. Students were first introduced to the disease project with a document (Appendix
B.1) and an in-class presentation on the internet resources available for researching these
diseases. The presentation focused on two databases hosted by the National Institutes of
Health (NIH): Online Mendelian Inheritance in Man (OMIM) and the Genetics Home
Reference. These databases provide extensive information regarding human genetic
diseases. OMIM is more technical and extensively references the scientific literature; it is
equivalent to hundreds of review articles in a database format. The Genetics Home
Reference site is more user friendly, presents information that is more accessible to the
layman, and provides information on disease advocacy and support organizations. The
presentation also introduced the class to websites and search engines for investigating the
scientific literature, especially Google Scholar and Pubmed (hosted by NIH). I also
encouraged the judicious use of Wikipedia, as a repository of basic and non-controversial
information (although it may not always be apparent what entries on Wikipedia belong to
this category). Finally, students were given a list of 15 human genetic diseases and
encouraged to briefly research the diseases on the list, choose one that would be their
focus of their paper, and write a brief summary of their chosen disease's characteristics.
With my permission, two students chose diseases not originally on the list; these
additions will be incorporated in the next iteration of the class. Students were required to
convey their choice as one of the assigned homework questions due the second Tuesday
class of the semester.
Stage 2. The second stage of the project required the students to find a peer-reviewed
primary research paper (not a review) from the literature on their chosen disease and
provide a summary of this paper. The structure of this summary was provided to the

students in the document included in Appendix B.2. These assignments allowed me to
ensure that the students were discovering appropriate scientific literature and provided
them with a framework for critically reading the scientific literature, and for restating the
often technical language in journal articles in their own words. These assignments were
due the third (choosing an article) and fourth (summarizing the article) Tuesday classes
of the semester.
Stage 3. The third stage in the project was a list of 10 references on the students' chosen
disease topic that would form the basis for their research. This assignment allowed me to
ensure that students were accessing recent, relevant, peer-reviewed scientific literature for
use in their research. This assignment was due in the sixth Tuesday class of the semester.
Stage 4. The next stage of the project was an outline of the paper, following the structure
provided in Appendix B.3 as a guide. This document provided the students with a
description of the major sections their paper could contain, and specific questions their
research should answer. The outline was due Thursday of the eighth week of the
semester.
Stage 5. The fifth stage was a draft of the final paper. The draft was to be complete, with
proper formatting, citations, and polished spelling and grammar. These drafts were
carefully graded and commented to provide the students with the necessary feedback to
write a high-quality final draft, and if all the comments were addressed, the final draft
received a high grade. The drafts were due on Thursday the 14th week of the semester.
Stage 6. The final stage in the project was the completed research paper, due the Tuesday
of finals week.
4. Analysis of student learning
Gender effects on student performance: Student grades were comprised of homework
assignments, the stages of the research paper, and three in-class exams; the majority of
class points were assigned to the exams (60%). Exams consisted of a mix of multiple
true/false, short answer, and problem-solving questions.
Unexpectedly, a stark and statistically significant effect of gender was observed on the
distribution of class grades (Figure 1). This effect was most pronounced for the three
exams, as the grade distribution was the widest (greatest variance) for this component of
the class, but was also observed to a lesser extent in the distribution of final grades that
included homework assignments and the research paper. In all cases, the nine female
students significantly outperformed their 14 male counterparts. This effect was strongest
for exam #1, where the median female student score was 92, while the median male
student score was 78.5 (P-value = 0.001). On each exam, the top three, two, and five
scores all belonged to female students (exams 1,2, and 3 respectively); and the top five
final grade scores were all given to female students.
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Figure 1. (A) Boxplots of grades for three in-class Exams and the Final Grade
(%) for the semester, separated by student gender. Female student
distributions are indicated in red; male students in blue. Outlier points are
indicated as circles. P-values from a Mann-Whitney test of the difference
between median exam scores for female and male students are indicated
above the boxplots. The grades for Exams 1 and 2 were scaled by adding four
and eight points to each score, respectively, which resulted in some (female)
students earning > 100 points for the exam. One female student who stopped
attending the class was excluded from the plot for Exam 3 and the Final
Grade, as she did not take the exam or finish the final project. (B) Distribution
of final letter grades separated by gender.
As there is currently only data from one year of this course, it remains to be seen whether
this result reflects a general trend among students choosing to enroll in Human Genetics,
or whether this was merely a one-time effect.
Human Disease Review Paper: At all stages of the review paper project, feedback was
provided to the students.
Most students correctly identified relevant primary literature sources for their first paper
(Stage 2). The most common error at this stage was choosing a review paper that did not
present new data or experiments (four students initially chose review papers). This error
was unsurprising, since the distinction between review articles and articles that present
new results is most likely unknown to students who have not had extensive experience
with the scientific literature, and not always easy to discern (although three of the chosen
review articles did explicitly state that they were review articles in the abstract). Other
inappropriate choices included a study that focused very narrowly on a treatment of one
specific manifestation of the disease, rather than the underlying genetic basis or more
general therapeutic or surgical treatments. Students were provided with this corrective

feedback over email, and all students selected appropriate papers for their summaries on
the second try.
Student summaries of the first paper were largely acceptable, suggesting that the template
provided in Appendix B.2 provided them with enough structure to allow them to dissect
the primary literature.
Student lists of 10 relevant peer-reviewed publications (Stage 3) were also all acceptable,
suggesting that the instruction provided in Stage 1 and the feedback on the first paper
choices sufficiently enabled the students to navigate the scientific literature.
Outlines of the research paper (Stage 4) were assigned mainly to encourage the students
to make substantial progress on their research well in advance of the deadline for
completing the final product, and thus students were given full credit for completing the
assignment on time, and minimal feedback was provided on the structure or content of the
outline. Outlines ranged from minimal (Appendix C.1) to virtually completed final papers
(Appendix C.2).
The first drafts of the research papers, predictably, showed a wide range of quality, from
polished, completed papers that required minimal revision before submitting the final
version, to drafts that were incomplete, poorly structured, and replete with grammatical
errors. By far the most common errors involved the use of citations, particularly their
formatting. Many students used a numbered citation format, but failed to order the
citations by their appearance in their paper. Other students used an (author, year) citation
format but failed to include the year in the in-text citation. Some students repeatedly
cited the same source in multiple consecutive sentences, rather than including a single
citation at the end of the section. Multiple students failed to adequately cite the literature
throughout their paper; two students did not include any in-text citations at all, and one
student failed to provide a bibliography of their references. These errors were
unsurprising, given that most of these students likely had little or no experience with the
citation style in scientific publications, and all errors of this kind were readily corrected
for the final version of the paper.
Nine examples of both the first and final draft papers are provided in the appendix.
Comments and suggestions for improvement were provided on hard copies of the first
drafts and returned to the students. The first three examples (Appendix D.1, Appendix
D.2, and Appendix D.3) represent the best submissions - cases where the first draft was
virtually complete and required minimal edits for the final draft and students received
perfect grades on both drafts.
The next three examples (Appendix D.4, Appendix D.5, and Appendix D.6) represent
average student submissions. These first drafts all required significant modification
before the final version and were all scored at 70%. In addition to formatting and
grammatical errors, the first drafts in this group required extension and elaboration of one
or more sections of the paper. These three students varied in the success with which they

improved their paper for the final version, earning a 95%, 97%, and 92% on the final
draft (Students 4, 5 & 6 respectively).
The final three examples (Appendix D.7, Appendix D.8, and Appendix D.9) represent
low-quality student papers. The first drafts were scored at 60% (Students 7 & 8) and
80% (Student 9). The first drafts from students 7 & 8 were all incomplete in some way
and required extensive modification. The first draft from student 9 was largely complete
and required only minor edits and some changes to formatting and citations, but many of
these changes were not incorporated in the final version, leading to only a mild
improvement in score for the final draft (90%). Both students 7 & 8 did improve their
papers for the final version, scoring a 83% and 87% respectively, but these final papers
were still of poorer quality than the average paper in the class.
5. Planned Changes
I felt that the mix of projected slides and writing on the board worked well and allowed
the students time to take careful notes, while also enabling me to use relevant figures and
tables from the textbook or the literature to illustrate relevant concepts. The exam
structure also succeeded in identifying what concepts the students did and did not learn.
On each of the first two exams, the students did very poorly on one question (overall
scoring 33% and 22% of the total possible points); the points corresponding to these
questions were then added back each student's exam. In future classes, I will either make
an extra effort to convey the concepts assessed by these questions, or rewrite the exam
questions to try and better match what was taught.
In future iterations of this class, I intend to increase the time spent both in and outside of
class on reading and interpreting the scientific literature. The assigned readings and inclass discussion of the papers clearly engaged the students and conveyed to them both
scientific knowledge but also how that knowledge is obtained - something that is not as
readily apparent in textbooks. Ideally, the class would have no textbook but would rely
solely on primary scientific literature, review articles, and some science writing for the
lay public; but it may be a few more iterations before that becomes possible.
Many aspects of the review paper project went well. In the future I intend to incorporate
two changes to this project. First, the students needed more practice restating complex
and technical scientific language in their own words. This was clearly a challenge for
most of the students; a few approached this problem by extensively quoting the articles
they read in their paper, which, although ethically defensible, neither encourages
synthesis of the information nor makes for very readable text. This will be a significant
challenge, given how extremely technical and detailed the relevant literature is; but
nonetheless worth attempting. I think doing this together as a class for one paper, before
each student summarizes a paper on their chosen disease topic, would be the simplest
way to provide the class with this practice. Second, I intend to provide more detailed
feedback at the outline stage of the project. I would like to give the students freedom to
focus on the aspects of their research topic that interest them the most, and would like to

avoid constraining them too much with prescribed templates and formats; there is already
plenty of that in Appendix B.3. This motivated using the outline solely as a guard
against procrastination, and not critiquing the content of student outlines. However, I
think this is outweighed by the benefits of being able to provide students with feedback
regarding which aspects of their papers could be more or less detailed, and encouraging
them to find more or different source articles early in the writing process. Requiring both
a
"draft" and final version of the outline could also allow me to set a higher bar for the final
draft of the outline, aspiring for all students to produce a document on par with the best
outlines submitted this semester (Appendix C.2).
6. Summary and Synthesis
The first iteration of the human disease review paper, although not without flaws, seemed
to be largely a success. Even the lowest-scored review papers were substantial works of
research, and students clearly learned many concepts and details regarding their chosen
disease. Informal student feedback indicated that students enjoyed the project, and found
the staged structure helpful in guiding their research and writing and preventing
procrastination, as was intended. Although it may be modified, I intend to include this
project in future iterations of the class.
The Peer Review of Teaching Project was unquestionably useful in helping me to
develop Human Genetics and design the human disease project. But I feel its benefits go
beyond this specific course. By facilitating discussion of pedagogy and encouraging
instructors to approach teaching as if it were research (designing experiments and
collecting data on student learning), this project helped me to think more critically and
carefully about my teaching; about what my expectations of student learning are and how
to match my teaching to help students meet those goals; and empowered me to actively
and effectively work to improve my teaching.

Appendices
A. Course syllabus for Human Genetics, Spring Semester 2016
B. Teaching materials for the human genetic disease research project
B.1. Introduction to the project and entry points into the scientific literature
B.2. Guidelines for summarizing a scientific article
B.3. Suggested format for structuring the outline and research paper
C. Sample student outlines for the genetic disease research paper
C.1. Minimally acceptable outline ("Celiac Disease Outline")
C.2. Extensive and outstanding outline ("Hutchinson-Gilford Progeria Syndrome")
D. Sample student first and final drafts of their research papers
Examples of high-achievement papers
D.1. Student #1 rough/final drafts ("Celiac Disease Review")
D.2. Student #2 rough/final drafts ("Hutchinson-Gilford Progeria Syndrome")
D.3. Student #3 rough/final drafts ("Lesch-Nyhan Disease")
Examples of middle-achievement papers
D.4. Student #4 rough/final drafts ("Marfan Syndrome")
D.5. Student #5 rough/final drafts ("Primary Ciliary Dyskinesia")
D.6. Student #6 rough/final drafts ("Parkinson's Disease ")
Examples of low-achievement papers
D.7. Student #7 rough/final drafts ("Werner Syndrome")
D.8. Student #8 rough/final drafts ("Sickle Cell Disease")
D.9. Student #9 rough/final drafts ("Analyzing the Genetic and Clinical Aspects
of the Mutation in the Cystic Fibrosis Transmembrane Regulator Gene ")

Appendix A
BIOS 412/812: Human Genetics
Spring 2016 syllabus
Class meets Tuesday and Thursday 11:00-12:15 PM, Beadle Center 176
Instructor:

Dr. Colin Meiklejohn, Assistant Professor, School of Biological Sciences
Office: 302A Manter Hall
Office hours: scheduled by appointment
email: cmeiklejohn2@unl.edu

Textbook:

Genetics and Genomics in Medicine. Strachan, Goodship and Chinnery
(the digital version is a cheaper option)
Clickers are required

Course description and learning objectives: This course focuses on advanced concepts
in genetics, with a focus on human biology and applications of this knowledge to medical
diagnosis and treatment. This includes mechanisms of inheritance, the nature of genetic
variation, how this variation is expressed, and how this variation exists in populations and
over evolutionary time. In fulfillment of the ACE10 learning outcome ("generate a
creative or scholarly product that requires broad knowledge, appropriate technical
proficiency, information collection, synthesis, interpretation, presentation, and
reflection") you will write a synthetic review paper on a human genetic disease. Through
this project you will learn to search scientific literature; how to read and interpret the
scientific literature; and how to write a short review of recent scientific publications on
the disease.
Expectations:
BIOS206 (General Genetics) is a prerequisite for Human Genetics. I therefore assume
that students are familiar with the molecular and cellular basis for biological inheritance,
mechanisms and control of gene expression, the basic structure of the human genome,
and the segregation of alleles in populations.
For each lecture topic, you will have assigned reading and questions about the reading.
The questions will be posted on Blackboard and are due by noon the day before class.
These assignments are due the day before class so that we can spend class time focused
on the concepts that are challenging to the most students; I need the time to adjust the
next day's lecture based on your answers. Completing these assignments is part of your
grade; but you will get full credit so long as you make an honest effort to answer the
questions to the best of your ability.
I expect that you will come to class, read the textbook and assigned papers from the
scientific literature, do the assigned homework problems, think, have fun and use logic
over memorization. Please take advantage of office hours if you are struggling with the
material, sooner rather than later.
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Learning in groups is encouraged, but this is only effective if all group members are
contributing. The reading assignments may be done together with other students, but if
someone else is doing most of the work, you will likely get poor exam grades. Copying
someone else’s homework and turning it in as your own work is not only a violation of
the Student Code of Conduct (for both students), it is an ineffective way of learning the
material and preparing for the exams.
Evaluation and grading: Your course grade is based on three midterm exams,
homework assignments and a synthetic review paper investigating a human genetic
disease. Each of these 5 components (3 midterms, homework, research paper) comprises
20% of the final grade. Depending on the results, midterm exam scores may be scaled.
Final grades will be determined as follows (out of 500 points):
495 (99%) A+
460 (92%) A
450 (90%) A-

440 (88%) B+
410 (82%) B
400 (80%) B-

390 (78%) C+
360 (72%) C
350 (70%) C-

340 (68%) D+
310 (62%) D
300 (60%) D-

Academic integrity: Students are expected to adhere to guidelines concerning academic
dishonesty outlined in Section 4.2 of University’s Student Code of Conduct. Violations of
this policy will result in a minimum sanction of a grade of zero being given for the
graded item on which the violation occurred, and may include other actions, such as an F
for the course. All incidents will be reported to the Dean of Students. Behavior and
remarks that disparage persons or activities in the course, or detract from a serious
learning environment are not tolerated.
Email policy: Students are encouraged to contact the professor via email; however,
please be respectful in your use of email. Many details about the course can be found in
this syllabus, and conceptual questions are better discussed in lecture, office hours, and
study sessions. Please do not fill the instructors' inboxes with every question that may
arise regarding course material. Email is a good way to schedule appointments and
conduct course-related business. When you do email, it should be considered a formal
means of communication, and messages must be structured accordingly. This means that
each email must include an informative subject header, an appropriate salutation,
complete sentences with accurate spelling and punctuation, and an appropriate closing
and signature. Emojis are acceptable. Emails that do not follow this structure may or
may not be answered. These rules will help prepare you for virtually any future
employment, as email is a ubiquitous form of professional communication.
Students are strongly encouraged to send email through Blackboard or from @huskers or
@unl email address. In the past I have experienced problems receiving email from
services such as yahoo and rocketmail, and so messages sent from these accounts may
not be answered.
Students with Disabilities: Students with disabilities are encouraged to contact me, or a
teaching assistant, for a confidential discussion of their individual needs for academic
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accommodation. It is the policy of the University of Nebraska-Lincoln to provide flexible
and individualized accommodations to students with documented disabilities that may
affect their ability to participate fully in course activities or to meet course requirements.
To receive accommodation services, students must be registered with the Services for
Students with Disabilities (SSD) office, 132 Canfield Administration, 472-3787.

Learning Goals
Background material
• Explain the relationship between nucleotides, DNA, genes,
chromatin, nucleosomes, chromosomes
• Describe DNA replication and transcription
• Describe the processes of genome replication and cell division
• Compare and contrast mitosis and meiosis
• Explain homolog pairing and recombination in meiosis
• Describe the difference between introns and exons and explain
splicing
• Explain the genetic code and the role of RNA molecules in gene
regulation, including transcription and translation.
• Describe the structure of the human genome, explain gene families
and repetitive DNA
• Explain and diagram DNA cloning, PCR, and DNA sequencing
• Explain the principles and uses of nucleic acid hybridization
• Explain the process of mutation and the generation of genetic
variation
• Describe the structure of genetic variation in human populations
• Explain the signatures and consequences of natural selection acting in
human populations
• Perform genetic inference based on segregation of genotypes and
phenotypes in families and populations
• Calculate genotype frequencies from allele frequencies under HardyWeinberg equilibrium
• List the classes of cis-regulatory sequences, trans-regulatory proteins,
and small regulatory RNAs and how they regulate gene expression
(both transcriptional and post-transcriptional regulation)
• Explain how chromatin modification regulates gene expression
• Describe the role of epigenetics in human diseases
• Describe how genetic variation results in disease
• Describe the role of repetitive DNA in disease
• Predict transmission patterns of chromosomal abnormalities
• Describe genetic studies used to understand disease inheritance
• Describe genetic treatments and genetic interactions with drug
treatments
• Describe the genetics and progression of cancer
• Explain the advances derived from genomic studies of cancer
• Compare and contrast technical and ethical aspects of genetic testing

Strachan et al
reading
Chapters 1 & 2

Chapter 3
Chapter 4

Chapter 5

Chapter 6

Chapter 7

Chapter 8
Chapter 9
Chapter 10
Chapter 11

Appendix A

Course Calendar
January 19
Identify human disease topic
January 26
Identify recent scientific publication on chosen disease
February 11 Synopsis of recent publication due
February 11 Exam I
February 25 List of citable publications
March 15
Review outline
March 17
Exam II
April 5
Review rough draft
April 28
Exam III
May 3
Review paper

Human genetic disease project

Appendix B.1

This semester you will write a synthetic review paper on a human genetic disease.
Through this project you will learn to search scientific literature; how to read and
interpret the scientific literature; and how to write a short review of recent scientific
publications on the disease.
The first step is to choose from one of the human genetic disorders listed below. These
disorders vary in their severity, quality of life, genetic basis, and currently available
treatments. You can learn about each of these conditions from many online sources,
which you will also use to find scientific articles about the condition you choose to
research:
Google (search, news, scholar)
Wikipedia
*Genetics Home Reference (http://ghr.nlm.nih.gov/)
*Online Mendelian Inheritance in Man (OMIM - omim.org)
Web of Science: used to find primary (journal) articles and review articles in biology and
other scientific disciplines
PubMed: provides access to Medline, used to find primary (journal) articles and review
articles in the biomedical sciences
EurekAlert!: features science, health and technology news; sponsored by the American
Association for the Advancement of Science (http://www.eurekalert.org/)
Science Daily: breaking science news stories and feature articles
(http://www.sciencedaily.com/)
Human disease topics
Angelman syndrome
Beckwith-Wiedemann syndrome
Beta thalassemia
Celiac disease
Cystic fibrosis
Duchenne and Becker muscular dystrophy
Hutchison-Gilford syndrome
Leigh syndrome
Lesch-Nyhan syndrome
Marfan syndrome
Parkinson disease
Prader-Willi syndrome
Sickle cell disease
Tay-Sachs disease
Werner syndrome

Human genetic disease project

Appendix B.2

This assignment is worth 2% of your course grade, and is due at the beginning of
class on Tuesday, February 9.
The second step in this project is to write a summary of the primary literature article you
have selected on a human disease. The goal of this exercise is to help familiarize you
with the structure of a scientific paper and how to extract information from them. The
following sections of your synopsis correspond to the sections of a typical scientific
article, although not all articles will indicate each section with an explicit header. For
each section, write a few sentences or a short paragraph addressing the prompts listed
below. Given the technical nature of these articles, describing the methods and results in
your own words may be significantly challenging; however this challenge is precisely the
purpose of this assignment. Copying a sentence verbatim from the article is not
acceptable.
Abstract
Write 1-2 sentences that re-state, in your own words, a result highlighted in the paper's
abstract.
Introduction
What aspect of the disease (genetic basis, phenotypic manifestation, treatment options) is
addressed in this paper?
Methods
Summarize one of the main experiments in the paper as follows:
- Describe the authors' hypothesis or hypotheses
- Describe at least one experiment that they do to test their hypotheses
- What is the logic behind this experiment?
Results
What type of data did the authors collect?
What is the main result to come out of this experiment?
What conclusions do the authors draw from their results?
Future directions
What are the implications of this work for this particular disease? How will the research
(eventually) lead to improved quality of life for individuals with this disease?
Describe one experiment that could be done as a follow-up to the experiments described
in the paper.
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Human Genetic Disease Research Project
The following outline provides a recommended structure for your disease research
paper. Your paper should include most or all of these points, assuming that they are
applicable to your chosen disease. These recommendations may also help you identify
interesting primary literature articles that directly address one or more of these topics.
Provide an introduction to the disease
• Give a brief summary of the disease, including but not limited to: what defines the
syndrome, phenotypic range, physiological effects, prognosis, and quality of life.
• What is the epidemiology of the disease? Or, how often does the disease occur, in
which populations, how many births? Discuss details about higher incidence in
certain cultures, geographical areas, or other boundaries.
• What is the inheritance pattern? (autosomal, sex-linked, dominant, recessive, etc.)
Does this have a relation with the epidemiology?
• Provide a brief historical perspective of the disease. Who discovered it and when?
Who now supports research of it? Is the disease in the news? What advocacy groups
exist for the disease?
Define the genetic component of the disease
• What gene(s) underlie this disease, and how was the genetic component discovered?
• What would the karyotype of an affected individual look like (if different from normal)?
• What is the wild-type role of the gene?
• What are the most commonly reported mutations?
• What are the population genetics of the disease alleles? How frequent are disease
alleles, and are there differences in frequencies between populations? What
selective pressures are hypothesized to act on genotypes with one or two copies of
the disease allele(s)?
Describe the molecular biology and biochemistry of the disease
• What is the phenotype of the disease at the cellular level? What cells or tissues are
involved?
• Does the gene(s) encode a protein? What does the protein do? Is the protein
involved in a known pathway?
• How does the mutant form of the gene affect the cell?
• Find the homolog of the protein in rhesus monkey, mice, and Drosophila. Is the
mutation in a conserved region?
Clinical aspects and organismal phenotypes
• Diagnostic tests
• Variability in phenotype: penetrance and expressivity
• Role of the genetic element in other diseases
• Animal models
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Issues for the affected individual and treatments/prospects
• What are the major challenges faced by individuals with the disease?
• What is the current state-of-the-art in detection, treatment, or avoidance (e.g.
screening pre-implantation embryos)?
• What are some potential treatments that have been proposed or are in research and
development (e.g. clinical trials)?
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Celiac disease belongs to the class of autoimmune disorders in which an immune
response is mediated upon the body’s own healthy tissues, causing tissue damage and
inflammation. The genomic region that has been associated with several autoimmune diseases is
the human leukocyte antigen (HLA) or major histocompatibility (MHC) region on chromosome
6. Upon the ingestion of foods containing the gluten protein, patients with celiac disease trigger
an immune response that results in a range of enteropathies that are most commonly
characterized by mucosal damage and villous destruction. Traditionally, a gluten-free diet has
been the most effective treatment, but emerging research has presented innovative treatments
that work at the molecular level, by binding and blocking the binding site of the antigenpresenting molecule HLA-DQ2 and/or HLA-DQ8 [1].
The immune system is extremely polymorphic; its genetic variation has been under
positive selection in order to maximize the number and types of proteins (MHC proteins and
others) that bind specific foreign molecules that might be pathogenic. As a result, fully
understanding the exact genetic components that contribute to an autoimmune disease is often
quite challenging. To further establish the complexity of an autoimmune disease, it is worth
mentioning that genes within the HLA region are packed into a small region amounting to only
about 2% of chromosome 6. And, as a result, a haplotype of this nature (where genes are within
close proximity to one another) tends to be clustered in genes that are inherited together as the
chance of the genes being separated by recombination is low [2].
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There are several major challenges celiac disease patients have to manage besides
adhering to a strict gluten-free diet. Celiac disease is associated with numerous other enteric
malignancies and autoimmune diseases that can afflict multiple body organs and systems
including endocrine, hepatic tissue, and the nervous system. The most common associated
disease is dermatitis herpetiformis, characterized by the formation of itchy skin lesions and
erythematous papules. Individuals affected with this disorder are also likely to carry HLADQ2/DQ8 alleles. Overall, patients can expect to endure more complications than those resulting
directly from celiac disease, such as diarrhea and abdominal pain [3].
The oldest historical records describing celiac disease come from the Greek physician
Aretaeus of Cappadocia between the 1st and 2nd centuries AD. The symptoms were reported, but
the exact cause was not. It was not until the 19th century that British physician Samuel Gee
would propose the idea that celiac disease is linked to diet, which was later confirmed in the
1950’s by Dicke and colleagues who established that foods containing gluten, including wheat,
barley, and rye, are the cause of symptoms [4].
Current consensus indicates that the worldwide prevalence of celiac disease is at about
1% of the general population, with higher incidences among females. However, some regions
show increased prevalence, such as Western Sahara, while other countries like Burkina Foso
have had no reported cases [1]. Celiac disease is a polygenic disorder that follows a complex,
non-Mendelian inheritance pattern that is centered about the HLA region in which certain alleles
associated with the disease show strong linkage disequilibrium, or nonrandom association [5]. In
addition, recent findings confirmed the differential expression of certain genes in children
patients as opposed to adult patients, suggesting an age effect [6].
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There are several key molecular interactions that underlie the symptoms of celiac disease.
The pivotal molecules are HLA-DQ2 and/or HLA-DQ8 antigens and T-cells, which interact
directly to generate the destructive autoimmune response. HLA-DQ2/HLA-DQ8 heterodimers
that are specific for gluten binding use a T cell repertoire (TCR) that binds gluten-derived
peptide antigens and present them to T-cells which then secrete inflammatory cytokines in
response. The unusual molecular structure of gluten proteins, which are nearly half composed of
proline and glutamine residues, which makes them more difficult to digest in the intestinal tract,
ultimately resulting in the formation of many small peptide fragments that are susceptible to
chemical modification by tissue transglutaminase and subsequent HLA-DQ binding [7].
There are many candidate genes at multiple loci in several chromosomes in HLA and
non-HLA regions that are suspected of contributing to the genetic risk of pathogenesis [1]. The
allele that shows the strongest association with celiac disease is HLA-DQ2 [8]. Furthermore, a
dosage effect has been observed. Children who inherit a copy of HLA-BQB1*02 (one of the
alleles that encode for HLA-DQ2) from both parents were found to be at a higher risk of
developing celiac disease than those who inherited the allele from only one parent [1].
It is important to note that the vast majority of people who carry the HLA-DQ2 or HLADQ8 predisposing alleles will not manifest celiac disease. It is only the majority of those who are
already affected with celiac disease that have been found to carry the HLA-DQ2/DQ8 allele.
This is a good indicator of other non-MHC allele factors contributing to pathogenesis, such as
epigenetics and the environment (diet). Surprisingly, recent evidence uncovered by genome-wide
association studies (GWAS) suggest that the vast majority of SNP’s that are associated with
disease occur in non-coding regions of the genome, including regulatory sequences (promoters,
enhancers, etc…) and non-coding RNA (ncRNA) genes [1]. A special class of noncoding
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RNA’s, microRNA, was found to be differentially upregulated as revealed by biopsies of celiac
disease patients and controls. Specifically, a miRNA known as miR-449 was found to be the
most upregulated. That miRNA also happens to be the one that targets mRNA’s that code for the
translation of the NOTCH1 inflammation regulator. In concordance with the finding, NOTCH1
was discovered to be at lower concentrations in the small intestines of patients with celiac
disease. Overall, however, not much data have yet been gathered in support of the role of
ncRNA’s in celiac disease [9].
Another epigenetic mechanism suspected to contribute to increased risk of celiac disease
is allele specific methylation, which also occurs in noncoding sequences. Using microarray
screening technologies, Hutchinson and others reported finding allele-specific methylation at
several expression quantitative trait loci, one of which was the long non-coding RNA DLEU1
that has been associated with celiac disease [10].
In order to obtain a good understanding of the disease and its mechanism, the focus of
discussion will shift to the actual site of action: epithelial cells of the small intestines. To start
off, the CD4 T cells that are specific for gluten peptides bound to HLA-DQ2/DQ8 have only
been detected in celiac disease patients [11]. Upon examination, T-cell receptor usage was found
to be biased among patients as opposed to controls, and a key non-germline encoded arginine
residue was discovered as part of the T-cell receptor structure and determined to be essential in
the binding of T cell receptors to HLA-DQ-gluten peptide complex [12]. On its own, a glutenderived peptide consisting mostly of glutamine and proline residues is actually weakly bound to
HLA-DQ2/DQ8 heterodimers and therefore will only trigger a weak response from T cells. To
induce high affinity, the action of tissue transglutaminase is needed to deamidate glutamine into
glutamate, essentially converting an electrically neutral amino acid into a negatively-charged
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amino acid. Upon tissue damage, transglutaminase enzyme is recruited and acts to immediately
modify gluten peptides, causing greater binding affinity between HLA-DQ2/DQ8 and the gluten
peptides, which ultimately leads to an elevated T cell response, increasing intestinal tissue
damage. Fundamentally, the T-cell mediated response is not triggered on a full scale upon the
encounter with the first gluten peptide, but rather in a snowball fashion [13].
Arguably, the most fascinating aspect about the molecular basis of the disease is the root
of the problem itself: why do gluten-derived peptides cause an immune response to begin with?
The answer lies in the pathogenic world. On the surface of small intestines, the extracellular
matrix is a major barrier between our cells and all sorts of other foreign microbes. But a common
theme in evolutionary biology is that host and parasites coevolve. In order to gain access to host
tissues, a parasite will secrete proteases that break down the extracellular matrix of the host. As it
turns out, like gluten, the extracellular matrix is unusually high in proline residues. Therefore, the
presence of high levels of prolines can be interpreted by the immune system as an attempt by
parasites to degrade the extracellular matrix and will respond accordingly [14].
Although the majority of the complexity of celiac disease is contributed to its polygenic
and epigenetic nature, the environment remains a critical factor in the onset of disease. And since
the primary site of action in the disease are the small intestines, the role of the patient’s intestinal
microbiome was interrogated. A study by Nistal el al., among other works, confirms the
observation that fecal samples from celiac disease patients display different microbiota
compositions than healthy individuals. They’ve also reported a significant difference in presence
of Bifidobacterium bifidum between untreated celiac disease patients and healthy adults. A
reduction in the diversity of B. bifidum was observed in treated celiac disease patients and
healthy adults but not in untreated patients [15].
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Other findings point to the possibility of certain genotypes influencing the composition of
the microbiome. The most relevant genotype here, HLA-DQ, has been found to be in association
with reduced B. bifidum [16]. This bacterial species is worthy of special and careful attention
because of the anti-inflammatory effects it induces. Upon the encounter with a gluten-derived
peptide bound to an HLA-DQ heterodimer, T cells produce pro-inflammatory cytokines such as
TNF-α and IL-1β. It was discovered that B. bifidum induces an inhibitory effect on the secreted
cytokines, and different strains of the bacterium correspond to varying inhibitory strength. The
proline-rich structure of gluten proteins render them more difficult to degradation by the action
of the body’s own proteases, allowing the proline-rich peptides to reach the lamina propria of
small intestines. Interestingly, the B. bifidum breaks down gluten peptides further by proteolysis
during digestion such that the gluten-derived peptides that reach the intestinal epithelia are of
different structural patterns than the other less degraded gluten peptides normally bound by
HLA-DQ antigens. This ultimately leads to a reduced or inhibited pro-inflammatory secretions
by T cells [17]. The fact that gut B. bifidum alleviates the automimmune inflammatory response
could potentially shed some light on alternative treatment methods.
An accurate diagnostic tool is to measure the concentration of modified gluten antibodies
in patient serum before and after the implementation of a gluten-free diet. If a significant drop in
gluten-specific antibodies levels is observed after introducing a gluten-free diet as opposed to
before, then one can conclude with significant certainty that the patient has celiac disease [7].
Another highly effective diagnostic method would be to perform serological tests on potentially
affected individuals while they’re on gluten-containing diet and measure the ratio of IgA
antibodies to tissue transglutaminase. If the results are positive, a duodenal biopsy may be
performed to confirm the results. Samples from the duodenum of the small intestines are
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examined for signs of villous damage or other features in the lamina propria that would confirm
the results. Moreover, a genetic test can also be used to confirm results or rule out the possibility
of a celiac disease. An individual who is negative for both HLA-DQ2 and HLA-DQ8 is a very
poor candidate for celiac disease [3].
The gluten-free diet has been the traditional method of treatment of celiac disease, and
perhaps the most effective since patients experience symptom relief and reversal of intestinal
tissue damage. Living in the western hemisphere where most cuisines have historically been high
in gluten-containing foods, it can be a challenge for some patients to completely rule out gluten
from dietary intake. However, keeping the patients well-informed about the seriousness of the
disorder may boost their motivation to abstain from gluten. There has been research efforts
aimed at developing effective treatment strategies, working at the molecular level, to block the
binding sites of HLA-DQ2/DQ8 that would otherwise bind gluten peptides. The trick here is to
design peptide analogs that bind HLA-DQ’s with higher affinity than gluten-derived peptides
[18]. Alternative and modern treatment strategies seem to be promising and theoretically
effective.
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Hutchinson-Gilford Progeria Syndrome
Introduction
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging disorder that begins to
manifest within the first year or two of life. Individuals with HGPS exhibit characteristic phenotypes of
aging, such as lipodystrophy, hair loss, skin discoloration or mottling, prominent vasculature, and a
beaked nose [1,2,3,4]. Due to the rapid and early manifestation of these phenotypes, these individuals
also have stunted growth in both height and weight, skeletal abnormalities of the cranium, mandible,
joints, and fingers (tufting), and cardiovascular complications [1,2,3,4]. Specifically, these individuals
often suffer from arteriosclerosis and atherosclerosis, generally resulting in death around age 13 on
average due to heart attack or stroke [1,3,4].
HGPS affects 1 in 4 million live births each year [3]. It was first described in 1886 by Dr. Jonathan
Hutchinson and in 1897 by Hastings Gilford, but it was not until 2003 that the genetic basis was
discovered [5]. Studies found that in 90% of HGPS cases, the disorder is caused by a de novo, noninherited autosomal dominant point mutation in the lamin A/C gene [1,6]. Due to this sporadic nature,
no frequency differences between cultural populations have been observed or documented. Current
research has been primarily focused on the cellular effects of this mutation, how these effects lead to
rapid phenotypic aging, and the utilization of this knowledge in developing potential treatments. The
continuation of HGPS research is further advocated for due to the potential knowledge that can be
gained about the normal aging process.

Genetic Component
The lamin A/C gene (LMNA) is located on chromosome 1 and normally functions to produce A
and C type lamin proteins [1,2,6]. These, along with type B lamin proteins, are intermediate filaments
that come together to form the nuclear lamina, a mesh-like protein scaffold underlying the nuclear
membrane [3,6]. The nuclear lamina supports the overall structure of the nucleus and interacts with
chromatin, membrane associated proteins, transcriptional regulators, and nuclear pore complexes [3,6].
Through these interactions, the nuclear lamina has been shown to play a role in chromosomal
compartmentalization and various nuclear activities such as gene expression and the movement of
molecules in and out of the nucleus [6]. Lamins A and C are both formed from LMNA through
alternative splicing and have nearly identical protein sequences, but differ in length [1,6]. In addition,
prelamin A must go through several post-translational modification steps before becoming mature lamin
A, whereas, lamin C does not require these additional processing steps [1, 2,6].
The C>T point mutation that causes the majority of HGPS cases is a synonymous mutation
located in the third position of codon 608 (position 1842) within exon 11 of the LMNA gene [1,3,4,6].
Even though this mutation does not alter the amino acid sequence, it activates a cryptic splice donor site
that interferes with normal splicing and results in a 150 nucleotide, 50 amino acid, deletion in prelamin
A molecules [1,3,6]. Within the deleted region is a cleavage site, ZMPSTE24, necessary for the removal of
the c-terminal farnesyl group and conversion of prelamin A to mature lamin A [6]. As a result, these
mutated prelamin A proteins, called progerin, retain the c-terminal farnesyl groups, which cause the
progerin proteins to remain attached to the inner nuclear membrane disrupting nuclear structure [4,6].
As progerin accumulates, the nuclear structure becomes increasingly abnormal resulting in
characteristic nuclear blebbing and instability [4,6].

Due to the important role that the nuclear lamina plays in overall nuclear stability, lamin genes
are not just present in the genome of humans, but are also present in many other organisms, such as
Drosophila and mice species. Drosophila have two different lamin genes, lamC that produces A type
lamins and DmO that produces B type lamins [7]. However, the lamin A proteins produced in Drosophila
are not farnesylated like in humans. This prevents the use Drosophila as model organisms for HGPS
because the lamC gene cannot be mutated to produce progerin [7]. Despite these differences, genetic
analysis has revealed that homologous lamin genes in Drosophila and vertebrates actually came from a
common ancestor, indicating a high level of conservation [7]. This conservation is further illustrated by
the presence of LMNA genes in mice and primates.
Mice have been widely used as model organisms for HGPS because following induction of a
similar C>T point mutation in the LMNA genes of mice, they begin to produce progerin and exhibit some
of the same phenotypes as individuals with HGPS [6]. In fact, analysis of knock-out mice models revealed
that HGPS disease phenotypes are not caused by haploinsufficiency because even though these mice
produced no lamin A, they did not have any nuclear abnormalities or other HGPS associated phenotypes
[4]. Based on these results, it was determined that the HGPS mutation works instead in a dominant
negative fashion since only one mutant allele is required for disease phenotypes and appears to out
compete or inhibit any sort of potential compensation by the normal allele [4]. However, these mice do
not exhibit all of the HGPS phenotypes present in humans and cannot be used as complete models of
this disease.
Effect on Cellular Function
LMNA is expressed in nearly all differentiated somatic cells through-out the body so any
mutation in this gene can affect the function of many different cell types, especially bone cells and
fibroblasts of skin, muscle, and vascular tissue [1,2,6]. In contrast, cells of the nervous system have been

found to express LMNA at substantially lower levels than other cells of the body [1,4,6]. As a result, the
production of progerin in nerve cells is minimal, which may explain why HGPS individuals show no
indication of neural deficits [1,4,6].
As previously mentioned, progerin causes abnormal nuclear structure because it remains
farnesylated and subsequently attached to the inner nuclear membrane. This disruption to the nuclear
structure is further intensified as progerin accumulates within the cell because progerin molecules come
together to form insoluble cytoplasmic aggregates that bind to the nuclear membrane and cause the
nuclear blebbing observed later on in the progression of the disease [8]. These progerin aggregates also
interfere with proper cell division because lamin A is normally present in an unpolymerized state during
mitosis [8]. As a result, this abnormal membrane morphogenesis can cause chromosome misalignment
during mitosis as well as disrupt proper nuclear division, which can lead to improper chromosome
separation and binucleation [8]. Mitosis was also observed to be further disturbed by chromosome
lagging during anaphase in HGPS cells [8].
Normal lamin A is known to interact directly with chromatin at specific heterochromatic regions.
These interactions promote proper chromosomal compartmentalization within the nucleus as well as
play a potential role in gene expression [3]. In a study done by McCord, progerin was found to interact
differently with chromatin than normal lamin A proteins causing an altered pattern of H3K27me3 at
numerous chromatin locations [3]. This histone modification is a repressive mark associated with
facultative heterochromatin commonly used in the regulation of gene expression [3]. Further analysis
revealed that these disease-related epigenetic alterations were present at several promoter sites,
resulting in deviations, both higher and lower, from normal levels of expression in corresponding genes
[3]. These histone alterations were also shown to result in loss of normal chromosomal
compartmentalization because they prevented normal overall association of chromatin with the nuclear

lamina [3]. The nuclear lamina is also believed to control the binding and release of lamin-associated
proteins from the nuclear periphery, which most likely regulate the expression of developmentally
regulated genes by either silencing or activating transcription [9]. Progerin was also shown to affect
these protein-chromatin interactions altering gene expression [9]. McCord further concluded that these
modifications to H3K27me3 occurred well before nuclear blebbing in HGPS cells indicating that these
alterations arise very early on and may be a potential cause for the rapid phenotypic manifestation of
this disease [3].
In a proteomic study, Rivera found dramatic differences in the level of certain proteins found in
HGPS fibroblasts compared to control fibroblasts [6]. An upregulation of glycolytic proteins and a
downregulation of proteins involved in oxidative phosphorylation, ATP synthase (complex V), and
translational apparatus proteins, ribosomal proteins, was found in HGPS fibroblasts [6]. These proteomic
alterations in HGPS cells indicate an evident switch from oxidative to glycolytic metabolism due to
defective oxidative phosphorylation. This defect in cell metabolism is called mitochondrial dysfunction
and is believed to contribute to the premature organ decline in HGPS individuals [6]. These same results
were also found through proteomic analysis of both heterozygous and homozygous progeriod mouse
models and ZMPSTE24-/- mice models [6]. The ZMPTSTE24-/- mice do not produce progerin, but do lack
the cleavage site necessary for the removal of the farnesyl group so are unable to convert prelamin A
into mature lamin A. Using these mice, it was illustrated that build-up of prelamin A has similar effects
on cellular metabolism as the build-up of progerin [6].
Upon analysis, Decker found that the overall telomere lengths in HGPS cells did not follow the
same chromosome specific pattern observed in normal cells, suggesting a more random arrangement of
chromatin in HGPS cells [1]. One such deviation discovered was that on average the telomeres were
shorter in HGPS cells and at least one chromosome in every HGPS cell analyzed had telomeres shorter

than the threshold for detection, which was not observed in any of the control cells [1]. However, the
chromosome in which these extremely short telomeres occurred was not consistent and varied between
HGPS cells [1]. Since telomeres become shorter with each replication and cell division, telomere length
is a critical factor in how many times a cell can divide. Therefore, it is believed that the overall shorter
telomeres in HGPS cells lead to the premature senescence that cause arterial changes and eventual
heart attack or stroke of HGPS individuals [1]. It is not yet clear why HGPS cells possess shorter
telomeres, but it has been found through studies of the normal aging process that shorter telomeres
may actually induce the production of progerin in normal cells later in life [2]. This gives insight into a
potential mechanism behind the very rapid accumulation of progerin and subsequent phenotypic
manifestation of HGPS.
Progerin was also found to negatively affect the multipotency and differentiation of
mesenchymal stem cells (MSCs) by increasing the sensitivity of MSCs to hypoxia [10]. This causes an
overall shortage of mesenchymal stem cells in HGPS patients, which are necessary for tissue
replenishment, leading to an overall reduction in the amount of certain differentiated cell types [10].
This same affect was seen on vascular smooth muscle cells, which presented with increased DNA
damage and nuclear abnormalities in HGPS cells [10]. These defects are, therefore, likely contributors to
the serious cardiovascular complications associated with HGPS.
Clinical Aspects and Associated Diseases
This disease is part of a group of 12 diseases known as laminopathies, each one resulting from a
different mutation in the LMNA gene that affects the proper processing of prelamin A [2,6]. Despite this
commonality, these diseases all present with a distinct set of clinical phenotypes associated with various
tissues including myopathy, cardiomyopathy, lipodystrophy, neuropathy, and premature aging [2]. HGPS
is generally diagnosed prior to two years of life based on stunted growth, lipodystrophy, and overall

failure to thrive [3,4]. These initial signs are rapidly followed by the onset of other characteristic
phenotypes associated with aging [4]. Genetic testing for the associated LMNA mutation can then be
performed to confirm the visual diagnosis.
HGPS exhibits complete penetrance. Due to the dominant negative affect of this mutation, the
presence of only one mutated allele is necessary to cause HGPS and will always result in HGPS [4].
Potentially due to the sporadic origin of this mutation, most individuals with HGPS are heterozygous for
the mutated allele [6]. This makes comparison of phenotypic severity between heterozygous and
homozygous individuals extremely difficult to achieve. However, using both heterozygous and
homozygous progeriod mouse models, Rivera was able to reveal that the effects of progerin, with regard
to mitochondrial dysfunction, is both dose and time dependent [6]. Phenotypic comparison between
heterozygous and homozygous progeriod mice revealed that homozygous mice exhibited disease
phenotypes at an earlier age and with increased severity than heterozygous mice [6]. Younger
heterozygous mice, 10 weeks old, also showed less severe phenotypes and mitochondrial dysfunction
than older heterozygous mice, 32 weeks old [6]. Together these results show how the amount of
progerin affects the phenotypic severity of the disease.
Progerin has been found in cells of individuals of advanced ages and therefore is believed to play
a role in the normal aging process [2]. In a study done by McClintock analyzing the aging process of
normal skin cells compared to HGPS cells, progerin was not only found in normal skin cells, but also
determined to increase in an age-dependent manner just as in HGPS cells [2]. However, the level of
progerin was still substantially lower in normal cells of even the most advanced ages compared to the
level of progerin in HGPS cells [2]. Although, the effects may not be as drastic in normal cells as they are
in HGPS cells, studies regarding HGPS have given incredible insight into the process of aging. Telomeres
have been shown to shorten over the lifetime of an individual and act as a sort of molecular clock

controlling the lifespan of cells and of individuals as a whole [1]. As previously mentioned, it is believed
that the shortening of telomeres due to replicative damage and cellular division may actually cause the
activation of the cryptic splice site in certain cells leading to the production of progerin in normal cells at
advanced ages [1,2,6]. This progerin production and accumulation would in turn cause the same cellular
affects observed in HGPS cells to occur in normal cells, thereby serving as a potential explanation for the
increased incidence of nuclear abnormalities, mitochondrial dysfunction, and reduction in
transcription/DNA repair seen in the normal cells of older individuals [2,6].
Health Issues and Treatments
The prognosis for individuals with HGPS is very bleak, with a 100% fatality rate [4]. As of now,
there is no cure for this disease and most of the treatments are geared towards pacifying the age
associated ailments caused by this disease. Studies have shown that HGPS individuals experience drop
out of smooth vascular muscle cells, reduced elasticity and thickening of arterial walls, and reduced
vascular compliance resulting in high blood pressure [4]. As a result, a great deal of emphasis is placed
on treating these cardiovascular complications, however, almost all individuals eventually die during
their adolescent years from heart attack or stroke [4]. Growth hormones are also administered in
attempt at increasing the overall height and weight of these individuals [4]. This treatment has proven
to be successful to some extent, but a large gap in overall growth still remains in comparison to healthy
children of the same developmental age [4]. Other ailments commonly exhibited by individuals with
HGPS include hearing loss, hyperopia, and joint abnormalities. These individuals remain surprisingly
mobile, however, despite joint abnormalities and cardiovascular issues, with majority testing within the
average mobility range for their age [4].
There are several treatments currently undergoing clinical trials aimed at combating different
molecular components of the disease. One such treatment focuses on the use farnesyl transferase

inhibitors, which inhibit the addition of the farnesyl group to prelamin A molecules during the early
post-translational modification steps [4]. By inhibiting the addition of the farnesyl group, the mutated
prelamin A proteins will no longer remain permanently attached to the inner membrane allowing for the
restoration of nuclear structure [4]. Clinical trials for this type of drug showed increase weight gain and
fat tissue, improved vascular stiffness, and bone mineralization resulting in reduced fracture rate [4,11].
The administration of this drug also extended the lifespan of individuals on average by about 1.6 to 2.4
years [11]. However, these outcomes only occurred in some treated individuals, but not all [11]. Another
treatment undergoing clinical trials is the use of isoprenylation inhibitors. In mice models, it was shown
that preventing progerin isoprenylation increased ATP synthesis and reduced overall mitochondrial
dysfunction [6]. The potential use of isoprenylation inhibitors in combination with farnesyl transferase
inhibitors has also been proposed and shown to enhance the beneficial outcomes of farnesyl transferase
inhibitors in early trial stages [6]. However, the use of isoprenylation inhibitors individually and in
combination with farnesyl transferase inhibitors is still under evaluation.
Rapamycin is another proposed drug currently undergoing clinical trials and evaluation. The
major target of rapamycin in the body is a central regulator of cell growth and various other cell
processes known as the mammalian target of rapamycin (mTOR) [12]. However, rapamycin has also
shown to induce macroautophagy, which is the normal process used by cells to get rid of damaged or
unnecessary components through lysosomal degradation [12]. Rapamycin has also been shown to
increase the solubility of progerin that has formed cytoplasmic aggregates [12]. By promoting autophagy
and dissolution of progerin aggregates, rapamycin has proven successful in decreasing the amount of
progerin accumulation in HGPS cells. This increase in progerin turn over has allowed for improvement
and even reversal of nuclear blebbing, restored H3K27me3 modifications, and extended the cellular
lifespan by an average of 30 days thereby successfully postponing cellular senescence [12].

In addition to the treatments currently undergoing evaluation, there are several more
prospective treatments not yet ready for actual application or clinical trials due to an increased level
complexity [5]. These treatments include RNA, gene, and cell replacement therapies. RNA therapy would
involve the removal or inhibition of the alternative splice site activated by the mutation whereas
targeted gene therapy would involve the actual repair of the mutated gene outside of the body followed
by its reintroduction into the body [5]. Cell replacement therapies would focus primarily on the use of
matched normal cells or stem cells from HGPS-iPS cell that have been genetically corrected [5]. Although
different in methodology, all present steep obstacles that will take a great deal of effort and time to
overcome prior to actual application. However, these treatments may hold the key to a more
permanent or even complete remedy to HGPS.
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Synthesis Paper
Topic: Lesch-Nyhan Disease
Lesch-Nyhan Syndrome (LNS) was not an officially diagnosed disease until 1964 in the
United States of America when two physicians, Lesch and Nyhan, recognized a pattern of
abnormal neurological function, self-mutilating behavior, and exceptionally high levels of uric
acid in the urine of two young brothers (Lesch & Nyhan, 1964). It is not surprising that the
recognition of LNS did not come until the 1960s. The disease is an “Orphan Disease”, meaning it
is exceptionally rare. For example, in the United Kingdom, a country with fifty-six million
people, there is an average of only four new cases per year (McCarthy, 2006). Overall, one out of
eight hundred thousand live births will be affected by Lesch-Nyhan (Hall, 2001). In none of the
research was it mentioned any specific population or geographical region being more prone to or
having higher incidence rates of LND. This could be due to the large percentage of mutations
leading to LND being de novo mutations instead of mutations being passed though families as
will be discussed later in this paper.
Soon after Dr. Lesch and Dr. Nyhan published their work describing the syndrome, more
cases were reported and studied. From the fifth family to be studied with a history of the
syndrome, the largest family being studied in that time period, a pedigree was created.
Combining the information from the five families, a team at the University of Virginia School of
Medicine was able to deduce that the inheritance pattern in LNS was X-linked recessive
(Shapiro, 1966). This was determined as only boys were affected and the ratio matched what was
predicted, one in four boys affected from unaffected parents. Females thought to be carriers due
to having an affected son showed slightly higher levels of uric acid in urine (Shapiro, 1966); this

supports the hypothesis of X-linked transmission as the phenotype of heterozygotes is slightly
altered.
Male to male dominant transmission as a pattern of inheritance was eliminated as a
possible hypothesis because of the evidence of female carriers having differing levels of uric acid
than average and because most boys with LNS at the time of this research were institutionalized
very early in childhood or died in infancy (Shapiro, 1966), leaving them unable to pass on
genetic information. Male to male dominant transmission could also be eliminated as a potential
hypothesis due to the presence of rare affected females. In one such case, an affected female had
a monozygotic twin who was unaffected by the disease. It was able to be determined through
fibroblast study that in the affected twin, the wild type allele has been silenced throughout the
body while in the unaffected twin the mutant allele had undergone the X-inactivation (Gregorio,
2005).
With the mode of inheritance determined through pedigree analysis and confirmed later
with the study of affected females, scientists began to search for the cause of this disease. Due to
the excessive amounts of uric acid produced by patients manifesting symptoms of LNS, it was
assumed by a team headed by J. Edwin Seegmiller that the disease must be caused by an enzyme
involved in purine metabolism losing its function (Seegmiller, 1967). The enzyme responsible
was indeed involved in purine metabolism: hypoxanthine-guanine phosphoribosyltransferase
(Seegmiller, 1967).
We know today that the gene that codes for this enzyme is quite large, fourty-four kb, and
contains nine exons in humans (Lapucci, 2006). Because LNS is caused by a single gene
mutation, an affected individual does not show a karyotype different than an unaffected
individual. This gene leading to LNS when mutated is called the HPRT gene, and it is located on

the long arm of the X chromosome at Xq26 (Torres G. P., 2012). In the year 2003, over two
hundred mutations had been observed within the HPRT gene leading to the symptoms of LNS,
and it was found that thirty percent of all mutations in the HPRT gene are de novo (Ohdoi,
2002). In 2015, twenty-seven new mutations at the HPRT locus were identified in a single study,
bringing the total of known HPRT mutations leading to LNS to over four hundred (CeballosPicot, 2015), which further emphasizes how this region of the X chromosome is prone to new
mutations or, if it is mutating at the same rate as the rest of the genome, the mutations are
occurring in areas where the affects produce a noticeable phenotype.
When the mutation at the HPRT gene is large scale, such as the deletion or a frame shift,
the phenotype associated with LNS will always be fully displayed in males who only possess the
mutant copy or in females who have the wild-type copy inactivated. Some of these large scale
mutations can be caused by incorrect splicing regulation as was the case in the twin study
discussed previously (Gregorio, 2005). The phenotype is always displayed because these
mutations lead to the production of hypoxanthine-guanine phosphoribosyltransferase enzymes
that have completely lost their function (Ceballos-Picot, 2015). Without a functional
hypoxanthine-guanine phosphoribosyltransferase enzyme, the patient is not able to properly
metabolize purines, leading to the build up of uric acid (Lapucci, 2006). This build up of uric
acid was a part of the original observations by Lesch and Nyhan which also included
“hyperuricema, mental retardation, choreoathetosis and self-destructive biting” (Lesch & Nyhan,
1964). Other phenotypes now associated with LNS are severe muscular dystonia and any form of
self-mutilation in addition to biting (Gregorio, 2005).
Clinically, it can be difficult to diagnose the forms of self-mutilation in LNS compared to
self mutilation that occurs with other neurological abnormalities such as autism. An important

study was done to shed light on this aspect of LNS. The study, preformed by a team led by Scott
Hall in 2001, showed that in in patients with LNS the self-mutilation is almost exclusively
sudden and violent, even initially when the behavior is first occurring. In patients with autism,
however, the self-mutilating behaviors usually increase gradually (Hall, 2001). It was also found
in this study that episodes of self-mutilation correlated with the child being left alone without
interaction with a caretaker (Hall, 2001), which the authors believe could be a sign that some of
the self-mutilating LNS phenotype may be tied to environmental factors.
In some individuals that exhibit the phenotype for LNS there is no mutation within the
HPRT gene. Using Real time PCR it was discovered that there was a mutation in the regulatory
sequence, and this mutation prevented the HPRT gene from being transcribed (Torres G. P.,
2012) . After testing both parents, the mother was determined to be a carrier for this regulatory
mutation (Torres G. P., 2012). Studies such as this further confirm that LND is is transmitted
though X-linked inheritance.
It is likely that this wide array of phenotypes affecting the muscular, renal, and
neurological functions of the body occur when the HPRT gene is no longer coding for a working
hypoxanthine-guanine phosphoribosyltransferase enzyme because purines are essential in all
tissues of the body and not limited to one specific cell or tissue type (McCarthy, 2006). For
example, patients with LND have been shown to have significant decreases in their white and
gray brain matter (Schretlen, 2013). Regions especially affected where the basal ganglia,
frototemporal, and the limbic system. These decreases in brain matter could imply that deficient
purine metabolism leading to the buildup of incorrect cellular products could affect brain growth
and development, especially in the regions previously mentioned (Schretlen, 2013).

Individuals who have a mutation in the HPRT gene that does not lead to complete loss of
hypoxanthine-guanine phosphoribosyltransferase enzyme function show a less severe phenotype
known as Lesch-Nyhan Variants (Ceballos-Picot, 2015). These mutations cause a phenotype that
has lower levels of cognitive impairment and no self-mutilating behaviors. Because these
phenotypes belong to a different disorder than LNS, it can be concluded that the phenotype range
for LNS is very small and without all of the symptoms, an individual does not actually have LNS
but instead a less severe variant disorder.
Currently, there is no cure for the phenotypes associated with LNS. Instead, efforts are
made by caregivers to manage physical and behavioral symptoms according to lesch-nyhan,org.
One of main symptoms that leads to a diagnosis of LND, the overproduction of uric acid, can be
managed with the use of a drug called allopurinol (Torres P. P., 2007). Allopurinol inhibits the
enzyme xanthine oxidase to prevent the body from synthesizing excessive amounts of uric acid.
The study preformed by Torres, Prior, and Puig showed that even after long term use of
allopurinol, patients did not have any adverse side effects, and the drug maintained its
effectiveness. It was found that with the use of this drug, patients were able to consistently have
seventy-four percent less uric acid excretion compared to their baseline levels. Managing the uric
acid levels in patients and returning them closer to the normal range does not lessen the other
symptoms of the disease such as self-mutilation, however (Hall, 2001).
Currently, behavioral therapy is the only method that can be used in an attempt to control
the self mutilating behavior found in LNS, according to lesch-nyhan.com. Pharmaceuticals, such
as s-adenosylmethionine, have been shown to provide little improvement or even worsened
behavior in LND patients (Dolcetta, 2013). In another study, 5-hydroxytryptophan in
combination with a peripheral decarboxylase inhibitor carbidopa and imipramine was used in an

attempt to control the self-mutilating behavior is LNS (Nyhan J. K., 1980). This treatment
appeared to be successful initially, but after three months each of the patients became immune to
the pharmacological effects, rending the treatment ineffective.
When behavioral therapy is used, it is important that it does not involve negative
punishment. Studies have shown that when negative punishment, such as an electric shock,
follow the self-mutilating behavior, the frequency of the self-mutilating behavior increases (Zilli,
2008). The authors of the study suggest that early in the progression of LNS, individuals
accidently injure themselves due to the lack of motor coordination associated with muscular
degeneration. After the accidently injury, improper dopamine signals in the basal ganglia
reinforces these behaviors, leading to individuals with LNS to begin to regularly self-mutilate
(Zilli, 2008). Therefore, when a negative punishment is applied following self-mutilation, it acts
as a reinforcement of the behavior because the improper dopamine signals are further stimulated.
In a review article published in 2000, restraint, in the form of splits, wheelchairs, and
keeping the patient from any sharp objects was the most common form of behavioral
modification (Olson, 2000). In fact, the removal of these restraints often lead to noticeable
distress in patients with LNS and increased levels of self-mutilating behavior. Treatments
including extinction, systematic desensitization, and play therapy used in conjunction were
shown to decrease the self-injurious behavior in several separate studies to the point where the
child no longer needed to be restrained (Olson, 2000). Hall found in his research that positive
and continued interactions with caregivers could also reduce the frequency of self-mutilating
behaviors (Hall, 2001). Even though there are some behavioral treatments shown to be effective,
many children still have all of their teeth extracted to prevent lip biting, cheek biting, and finger
biting (Hall, 2001).

There was a significant study published in 2015 by a team lead by Dr. Piedimonte that
shows potential to permanently treat the self-mutilating behavior associated with LNS. In this
case study, the team of doctors applied deep brain stimulation consistently to a twenty-nine-yearold patient via a bilateral electrode implant. The patient showed progressive improvement and
soon did not need his hands tied to prevent self-mutilation. Caretakers also reported a better
overall mood and willingness to help with his own needs. Five years later, there were no adverse
side affects and the self-mutilation behavior had been totally eliminated in the patient
(Piedimonte, 2015).
Due to the severe neurological impairments, self-mutilating behaviors, and stress on the
renal system due to the high levels of uric acid being excreted, it is not surprising that individuals
with LNS do not have a normal life expectancy; most individuals only survive into the second or
third decade of their life, and this lifespan length is only possible with diligent treatment and
therapy by the patient’s family (Nyhan O. J., 2014).
Because of the severe phenotypes, burden of care on family members, and short life
expectancy with low qualify of life by people suffering from LNS, many families with a history
of LNS undergo genetic testing in an attempt to avoid having children with this disease. Initially,
embryos with LNS were identified during pregnancy by culturing amniotic fluids (Halley, 1977).
The amniotic fluids were cultured on a coverslip and the autoradiographic analysis was available
a week later. By observing the karyotypes and the autoradiograohic analysis, a unaffected male,
affected male, and unaffected female were all correctly identified (Halley, 1977). However, the
amniotic fluids were not received until the mothers were in approximately their twentieth weeks
of pregnancy, and then it took almost two weeks to get the results back. This led the mother with
the affected male fetus to have an abortion at twenty-two weeks (Halley, 1977).

Today, there is technology available to completely avoid a pregnancy with a fetus
affected by LND instead of terminating an affected pregnancy, a practice that is much more
ethically accepted in current culture. This is done using in vitro fertilization (IVF). In a study
published in 1999, researchers were able to create blastocysts using the egg and sperm of parents
who already had one affected son using standard IVF procedure (Ray, 1999). After the
blastocysts had been dividing for three days, the healthiest were chosen to be genetically tested.
This genetic test was a single cell PCR amplification of DNA from a biopsied cell from the
healthy blastocysts. The PCR primers were designed to anneal to the region just before exon 8 in
the HPRT gene as the mother and affected son had both been previously found to have a deletion
in exon 8 (Ray, 1999). After five rounds of IVF treatment, a successful pregnancy and delivery
of an unaffected infant occurred (Ray, 1999). However, in all of the cycles there were always
several blastocysts that did not survive the biopsy procedure, making this method potentially
very difficult to preform successfully without patients who are willing to undergo multiple cycles
of IVF like the couple in the study. By 2003, this problem seemed to have been somewhat
reduced as a team in Australia were able to fertilize and biopsy five blastocysts with no
complications and implant two with the highest chances of surviving. This lead to the delivery of
a healthy, non-carrier, baby girl (Cram, 2003).
When studying LNS and the HPRT gene, it is possible to use animal models because the
HPRT gene is in a highly conserved region. According to ncbi.gov, the gene is conserved
between humans, Rhesus monkeys, chimpanzees, dogs, cows, mice, chickens, zebra fishes, and
frogs. 156 other organism contain an ortholog of the human HPRT gene. The animal model most
widely used is the mouse. In a review article published in 2016, it is pointed out that the animal
models of Lesch-Nyhan have some limitation due to mice having slightly different purine

metabolism pathways than humans. The models can only study one aspect of the disease at a
time, either the dysfunction in purine metabolism or the neurological problems leading to selfmutilation (Knapp, 2016). The mouse models have been useful for studying the importance of
the neurotoxins and depleted dopamine in the brain at different points in development. It has
been found that when young mice are exposed to the neurological conditions associated with
LNS that cause damage to the basal ganglia, they develop severe self-mutilating behavior similar
to the human phenotype (Knapp, 2016). When the mice are not exposed to this until they are
adolescents, however, they do not develop self-mutilating behavior despite similar levels of
damage caused to the basal ganglia (Knapp, 2016). Further research on this topic could greatly
increase scientists understanding of brain development in babies and children with a deficient
HPRT gene.
Because the mouse models are not completely representative of the human disease as
discussed above, research is now being done on human embryonic stem cells (Urbach,
Schuldiner, & Benvenisty, 2004). By using human cells that have been mutated to have the
HPRT mutation that appears in LNS, scientists are hopeful that they will be able to learn even
more about this disease. This knowledge could lead to a better understanding and future areas for
treatment for individuals affected with LNS.
There has also been a recent push for gene therapy as a cure for LNS as it is a disease
caused by a single gene mutation. However, gene therapy for the HPRT gene is not as easy as it
sounds. Because LNS causes severe neurological problems, the HPRT gene would have to be
replaced in brain tissue. This is currently not practical due to the blood-brain barrier; scientists do
not have a vector for inserting the HPRT gene that can cross this barrier (Cattelan, Dolcetta,
Hladnik, & Fortunati, 2013). In 2013, however, scientists did have success with replacing the

HPRT enzyme in the body instead of replacing the gene (Cattelan, Dolcetta, Hladnik, &
Fortunati, 2013). They did this by attaching the enzyme that was created in the lab to a protein
that had the ability to pass through biological membranes, which allowed it to enter deficient
cells. This was all done in vivo, meaning the patient would have to return for continued therapy
(Cattelan, Dolcetta, Hladnik, & Fortunati, 2013). This makes enzyme therapy a less appealing
option than gene therapy, but until a vector can be created or discovered to cross the blood brain
barrier, enzyme replacement therapy will continue to be as close to gene therapy as scientists can
get.
Research being tested in clinical trials is very slow for LNS; on the government website
for clinical trials, clinicaltrials.gov., there have been only four studies since 2003. One of these
studies was not able to be completed and one did not have results. The two studies that attained
results were for the drug Ecopipam. Ecopipam was a drug meant to reduce self-mutilation. Both
of these clinical trials were sponsored by a pharmaceutical company. In the original clinical trial,
the majority of the participants showed some improvements with mild side affects such as nausea
and respiratory infection. In the second trial when Ecopipam was compared to the placebo,
however, the study had to be terminated due to serious side affects experienced by the group
receiving Ecopipam such as dystonic crisis and unusual somnolence.
The slowness of current research is most likely due to the limited number of individuals
in the population affected with LNS. The amount of government funding on LNS is not enough
to be recorded as an independent category, meaning less than a million dollars were provided to
study the disease. Without government funding, all of the money for research has to come from
independent organizations.

In summary, LNS is an inherited X-linked recessive disorder. It is always expressed in
affected males and rarely in carrier females. The phenotype is caused by a large scale mutation in
the HPRT gene, leading to a lack of the enzyme hypoxanthine-guanine
phosphoribosyltransferase. Without this enzyme, individuals are not able to correctly metabolize
purines. This leads to severe phenotypes of self-mutilation, neurological conditions, dystonia,
and high levels of uric acid in the body. These symptoms will be expressed in the first years of
life. Thus far, research has been primarily based on genetic testing and IVF treatments to prevent
couples from having affected children. There is no cure for LNS, but improvements have been
made in managing the symptoms of the disease.
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Marfan syndrome was first described in 1896 by French physician Antoine Marfan, who
observed one of the characteristic symptoms, disproportionately long limbs, in a young girl who
he was treating. The genetic basis of the syndrome was discovered nearly sixty years later in a
study of patients with Marfan syndrome and their families. In 1991 (Dietz et al, 1991), it was
found that mutation of the FBN1 gene on chromosome 15 is responsible for the symptoms that
characterize Marfan syndrome.
The FBN1 gene encodes fibrillin-1, which is a large protein with several functions (Dietz
et al., 2005). Fibrillin-1 is exported from the cell into the extracellular matrix, which is made up
of molecules outside of the cell whose primary function is to connect cells to each other. One of
the main functions of fibrillin-1 in the extracellular matrix is as a structural component of
microfibrils. Microfibrils are important parts of two types of fibers in the extracellular matrix:
elastic and oxytalan fibers. These fibers provide stability and some elasticity to tissue. Along
with their structural function, these fibers also play an important role in the regulation of growth
factor concentration (Bonetti, 2009).
Marfan syndrome is caused by the mutation of the FBN1 gene (Dietz et al., 1991). Over
600 different Marfan-causing mutations of the FBN1 gene have been observed, varying in the
number of nucleotides changed and the severity of symptoms they cause. These mutations take
the form of frameshifts, splice errors, nonsense mutations, and missense mutations, which form
the majority of mutations found in the FBN1 gene (Hilhorst-Hofstee et al., 2010). While the
exact type of mutation may vary, the mutations that cause Marfan syndrome cause a misformed
fibrillin-1 protein to be created. The misformed protein will not be able to fold properly, leading
to improper association with the other components of the microfibrils (Robinson & Godfreyb,
2000). Since the fibrillin-1 is unable to enter the proper conformation, the strength of the

microfibrils is weakened. This also greatly harms the ability for transforming growth factor beta
(TGF-β) to bind to the fibers (Bonetti, 2009).
The inability of TGF-β to bind to microfibrils causes an excess amount of free TGF-β in
the body. The effects of excess TGF-β are where much of the new research on Marfan syndrome
is investigating. High levels of TGF-β cause lower muscle mass and increase the level of elastin
degradation. Elastin is another component of the elastic fibers. Degradation of elastin combined
with a misformed fibrillin-1causes further weakening of connective tissue. Some have proposed
that it is the high levels of TGF-β that cause many of the symptoms of Marfan syndrome rather
than the misformed fibrillin-1 (Benke et al., 2013).
Marfan syndrome is an autosomal dominant disorder, which means that an affected
parent has a 50% chance of passing the disorder onto each child they have. While most patients
with the disorder have a parent or other close family member with the disorder, it is estimated
that anywhere from 15-30% of the cases are caused by a new mutation that was not present in
either parent. The disease affects males and females equally and does not seem to be more
prevalent in any one race or ethnicity (Dietz et al., 2005). About 1 in 5000 people has Marfan
syndrome. A similar syndrome has been observed in mice with mutations to the homolog to the
FBN1 gene in that species (Pereira et al., 1999).
The symptoms of Marfan syndrome are highly variable. This is thought to be the case for
two main reasons. The first is the nature of the mutation of the FBN1 gene. While most of the
mutations that cause Marfan syndrome are caused by the change of just one base, it is thought
that the base or bases that are mutated can lead to somewhat different symptoms (Aoyama et al.,
1995). The exact correlation between genotype and phenotype is not well understood in Marfan

syndrome. The phenotype is variable even in patients who have had complete deletions of the
FBN1 gene (Hilhorst-Hofstee et al., 2010) If a complete deletion of the gene also leads to
variable symptoms, it seems clear that environmental, genetic, or epigenetic factors may be
having some sort of effect on the phenotype as well. This would seem to make studying the
differential effects of mutations on phenotype very difficult and would make results of such
studies unreliable at best. Perhaps the most well understood correlation between genotype and
phenotype in Marfan syndrome comes in those who have deletions in both copies of the FBN1
gene. These cases are highly rare as they require both parents to have Marfan syndrome and pass
the affected allele onto the child or for two de novo mutations to occur in the child. These cases
have shown that being homozygous for Marfan-causing FBN1 mutations is likely to be lethal
before birth and if the child is born they are unlikely to survive more than a few
months(Capotorti et al., 1959, Chemke et al. 1984, Schollin, Bjarke, & Gustavson, 1988). This
would seem to point to some phenotypic effect of the unaffected allele. Perhaps some of the
variation in phenotype is due to level of expression of the unaffected allele.
The most prominent symptoms of Marfan syndrome can be found in the skeletal system,
eyes, and cardiovascular system. This correlates with where elastic fibers are found in the
greatest abundance in the body. The symptoms affecting the skeletal system are the most visible
symptoms of Marfan syndrome. Individuals with Marfan syndrome often grow to be taller than
average and have long and thin arms, legs, and fingers (Loeys et al., 2010). Individuals with
Marfan syndrome often have highly flexible joints due to the lessened strength and elasticity of
their ligaments (McKusick, 1991).
One of the most common symptoms of Marfan syndrome is poor eyesight. Elastic fibers
are a large component of the ciliary zonules, which hold the lens in the eye. These fibers suspend

the lens and connect the lens to muscles which contract and expand to allow the lens to focus
light on the retina properly. One of the main issues that arises in the eye is that the lens becomes
dislocated (ectopia lentis) due the weakness of the ciliary zonules. In some cases the dislocation
is relatively minor and causes nearsightedness due to the lens being shifted closer to the pupil
and slightly up in the eye. However, the lens can move in any direction and cases of complete
lens detachment have occurred (Kainulainen et al., 1994).
The most serious symptoms of Marfan syndrome are those found in the circulatory
system, particularly in the aorta. As the primary point of exit for blood from the heart, the aorta
is very large and flexible as it endures a great deal of pressure. Much of this flexibility in the
aorta is due to elastic fibers. It is also thought that excess TGF-β causes enlargement of the aorta.
Those with Marfan syndrome are at high risk for aortic enlargement which can lead to aortic
dissection (tear in the aorta). Aortic dissection is very serious as it can lead to death very quickly
and suddenly due to lack of blood supply to other organs, heart failure, or complete aortic rupture
(Castellano et al., 2013, Jondeau et al., 2011).
Due to the discovery of other disorders that share many symptoms with Marfan syndrome
and the decreasing cost of genetic testing, the diagnostic criteria for Marfan syndrome has been
revised to place more of an emphasis on the FBN1 gene. The other two other criteria are lens
dislocation/myopia and aortic root Z-score, which is a measurement taken with an
electrocardiogram. If the Z score shows an aortic enlargement or possible dissection along with
an another of the two criteria, the individual is diagnosed with Marfan syndrome (Loeys et al.,
2010, Chubb & Simpson, 2012).

As with many dominant disorders, Marfan syndrome presents a more difficult problem.
In a recessive disorder, typically the disease phenotype is caused by the lack of a certain protein
or metabolite. However, in the case of Marfan syndrome the disease phenotype is caused by the
presence of a fibrillin-1 protein that is misfolded and does not function properly. In light of this,
it has been proposed that an RNA based therapy could be effective in treating Marfan syndrome.
The goal of such treatment would be to suppress the mutated allele that causes Marfan syndrome
while allowing the wild-type allele to be expressed (Kilpatrick & Phylactou, 1998). However, as
the study by Hilhorst et al. (2010) showed, Marfan syndrome could also be caused by
haploinsuficiency. So, if this is indeed the case, it would seem that down-regulating the mutated
allele would not be enough to fully treat the disease. To fully treat the disease the wild-type allele
would have to be up-regulated in order to give the patient the correct gene dosage.
Thirty years ago, the life expectancy of those with Marfan syndrome was only 30-40
years due to problems with diagnosing the disease and lack of treatment options. Though Marfan
syndrome cannot be cured, there are treatments available today that have increased the life
expectancy by more than 30 years (Fusar-Poli et al, 2008). One of the most common treatments
is the use of beta blockers which slow the heart rate and lower blood pressure and decrease stress
on the aorta. Another promising therapy is the use of angiotensin II receptor antagonists. Not
only do these antagonists reduce blood pressure, but they also reduce the levels of TGF-β (Keane
& Pyeritz, 2008). Even with these medications, aortic dissections are possible. If a dissection
does occur, surgery is generally undertaken to repair the tear with a graft (Castellano et al.,
2013).
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Primary Ciliary Dyskinesia (PCD) is a congenital, heterogeneous disease affecting the
ciliary structure and function [1]. It was first described in 1933, and the cellular basis of PCD
was described in 1976 [2]. PCD is present in all human races [1], and affects one out of every
16,000 individuals [3]. PCD is characterized by the immotility or ineffective beating of all cilia
present in the body [1]. This includes cilia of the upper and lower respiratory tracts, as well as
spermatozoa flagellae [4]. Situs inversus occurs in 50% of PCD cases. This is due to the inability
of embryonic cilia to shift the heart to the left side [1]. When situs inversus is present, PCD is
called Kartagener syndrome [4]. Patients have a 50% chance of developing situs inversus
because without normal cilia, there is an equal chance of normal and reversed visceral
transportation [1].
PCD is a heterogeneous disease, with many different genes affecting the disease
phenotype. However, patients in different subgroups of PCD, such as those having different
morphological defects as caused by different genes, appear to have the same clinical symptoms.
Physiological effects of PCD can include chronic sinusitis, due to decreased mucociliary
transport in the paranasal sinuses [1]. This can lead to anosmia [1] and the development of nasal
polyps [4]. Patients may also develop bronchiectasis by age two or three years, due to inadequate
mucociliary clearance of the lungs and chronic bronchitis. Because of the inadequate mucociliary
clearance, the patient must cough to transport secretions within the respiratory tract. PCD
patients also have a higher risk of otitis, otosalpingitis, and conductive hearing loss due to the
inadequate mucociliary clearance of the Eustachian tubes and the middle ear. In some cases, an
IgA deficiency and underdevelopment of the frontal sinuses are also seen in PCD patients. The
immune system is often normal in examined patients [1]. Daily airway clearance is necessary to
try to preserve lung function [5].
1

There is no formal registry to collect life expectancy data, but most papers say that life
expectancy of PCD patients is “near normal.” There is also no formal way to assess the average
age at which disability greatly affects quality of life. PCD has a wide range of symptom severity,
and therefore may affect patients’ quality of life in varying degrees. There are three general
periods in which the quality of life of a PCD patient may change. There are often several
symptoms during the initial diagnosis period, such as chronic lung infections and the need for
daily airway clearance and treatment with antibiotics. A patient may next experience a
“Cinderella period” during their adolescence and early childhood. It is named thus, because
while symptoms are still present, they are often well managed and treatment is required less
often. Finally, symptoms will become more prevalent and serious after the Cinderella period
during the third or fourth decade of life. Bronchiectasis that is already present may spread,
making lung infections more common and severe. Supplemental oxygen may be required, and
lung transplants may be considered. By the fifth decade of life, many patients report disability
due to lung impairment [5].
PCD has a relatively high prevalence because it is a heterogeneous disease [1]. It affects
one out of every 16,000 individuals [6], and is present in all human races [1]. The prevalence of
PCD is relatively high, considering that nearly all males are sterile and females have possibly
decreased fertility. It is common in parts of Sweden that are isolated or sparsely populated, as
this region is known as the “inbred island” [1]. PCD is also highly prevalent in two isolated
populations of Polynesians, however the disease is not associated with Kartagener syndrome in
this area [4].
It is likely that the inheritance pattern of PCD is an autosomal recessive pattern, as
determined from pedigrees [1]. One study found that the odds ratio between affected and healthy
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sibs is close to 1:3 [1]. PCD and Kartagener syndrome have also been observed in monozygotic
twins, suggesting that Kartagener syndrome is a part of PCD. However, there has not been a
large-serious study performed to confirm this. The first molecular demonstration of autosomal
recessive inheritance of lateralization defects was found when it was observed that in some
patients with PCD, the proper body asymmetry is the result of random determination of left-right
asymmetry. In two sibships, compound heterozygous mutations resulted in PCD with or without
left-right inversion.
It has been difficult for researchers to detect linkage in PCD, as it is a highly
heterogeneous autosomal recessive condition [4]. Studies can show that the parents of affected
persons are more likely to be relatives than average [1]. Based on this information, studies have
been looking into the question of if PCD is a result of a founder’s effect or rather a recurrent
mutation event. There have also been additional studies looking into alternative inheritance
patterns for PCD, such as autosomal dominant or X-linked patterns. In one such study, a mother
had five affected sons with three different fathers, which caused the researched to wonder if
another inheritance pattern is possible. Because PCD is a heterogeneous disease, it is possible
that there are different types of inheritance at play that all lead to dynein dysmorphology or
dysfunction [2]. In general, however, it is accepted that the inheritance pattern of PCD is
autosomal recessive.
PCD is the result of anomalies in the ciliary structure, leading to immotile or ineffective
cilia. Cilia are made up of nine outer doublet microtubules encircling two inner singlet
microtubules. This structural bundle is known as the axoneme. The characteristic “9+2”
microtubule arrangement is seen in a cross section of the axoneme using electron microscopy.
The axoneme is approximately 0.25 µm in diameter, and can vary in length depending on the cell
3

type and organism. Within the axoneme, inner and outer rows of dynein arms are attached to the
A tubule of each doublet microtubule, and the dynein arms extend out to the B tubule of the
neighboring double microtubule [7].
Cilia and flagella beat, with bends in the hair-like structures propagating from the
axoneme base. Ciliary and flagellar movement is due to the sliding between pairs of the outer
doublet microtubules within the axoneme. The dynein arms are the motor proteins in axonemes
and are responsible for movement. Formation and breakage of cross-bridges formed between the
dynein arm and the B tubule, and the binding and hydrolysis of ATP, help produce the force for
active sliding. Axonemal dyneins are composed up heavy, intermediate, and light chains. The
heavy chains can hydrolyze ATP, while the intermediate and light chains help secure the dynein
arm to the A tubule and may help regulate dynein activity. The dynein arms are active at
different times, based on their location, so that the axoneme can bend in two directions. Actively
sliding in one half of the axoneme will cause the cilia to bend towards one side, while sliding in
the other half will produce bending on the opposite side. Through this pattern, the cilia and
flagella are able to actively beat. Studies have found that the central singlet microtubules and
radial spokes, which link the central singlets to the A tubules of the outer doublets, may play a
role in controlling the bend of flagella [7].
Variations in the “9+2” pattern, seen in some protozoans, have demonstrated that the
central singlet microtubules are not necessary for axonemal beating, and that motility is still
present when there are less than 9 outer doublet microtubules, but with a lower frequency [7].
There are several genes that may contribute to PCD. The first gene with mutations found
to be associated with PCD was isolated from Chlamydomonas reinhardtii. Chlamydomonas
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reinhardtii is an unicellular alga with two flagellum that have similar axonemal structure to
human respiratory cilia and sperm tails [4]. Loss of function mutations in the human gene related
to the Chlamydomonas reinhardtii dynein IC78 result in PCD [6]. DNAI1 is also a possible
contributor to PCD. Axonemal dynein intermediate gene 1 DNAI1 is localized on 9p13-p21 and
is composed of 20 exons encoding a 699 amino acid protein. Axonemal ultrastructure is highly
conserved throughout evolution, which indicates that mutations to the genes responsible for this
structure are not favorable and therefore not selected for. DNAI1 had been found to be
responsible for some cases of PCD without situs inversus. Compound mutation heterozygosity in
DNAI1 results in PCD with situs solitus or situs inversus. This may be due to a splicing defect.
Mutations in DNAH5, a dynein heavy chain gene, have also been associated with PCD.
Mutations in the dynein heavy chain pseudogene DNAH7p have also been associated with PCD.
Dynein heavy chains are encoded by multiple genes, and therefore mutations to any of these
other genes may also play a role in PCD [4]. Mutations in DNAI1 and DNAH5 account for
almost 30 percent of all PCD cases. Cilia contain over 100 different polypeptides, therefore over
100 different genes may be involved. In many cases, the exact cause of PCD is unknown. At
least five types of ciliary defects can be distinguished morphologically, and these defects may
each have several genetic causes [1]. Transient ciliary abnormalities may also be produced by
environmental toxins or infections agents. No chromosomal defects have been found as the
underlying causes of PCD [2].
Homologs for the involved genes and proteins have been studied in rhesus monkeys,
mice, and Drosophila. An example is the iv mice strain kept by Layton, which was used to study
situs inversus, as well as the hpy mouse mutant, which was used to study male sterility in PCD
due to sperm immotility [2]. Another study with mouse mutants who were defective in genes
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required for cilia growth (Hfh4) or beating (Kif3B and Kif3A) demonstrated a link between cilia
motility and lateralization [4].
Many ultrastructural subtypes of PCD seen by electron microscopy, but they all produce
the same clinical features [1]. PCD and Kartagener syndrome are associated with missing or
abnormal dynein arms, abnormal radial spokes, and missing central pair of microtubules [4].
Disease cilia had absent or abnormally short dynein arms or the spokes were short or absent. A
reduction in number of dynein arms and in their length was most common abnormality found in
studies [1]. In some cases of PCD, cilia were also found to have random orientation. In such
cases, cilia had no ultrastructural defects, but lacked a fixed orientation [1].
Diagnostic tests for PCD include examining the ciliary ultrastructure through
transmission electron microscopy [1], as well as measuring the nitric oxide levels as a screening
process [5]. Dynein and microtubule structural defects viewed using election microscopy are the
main diagnostic clues that a patient has PCD. Nitric oxide levels are chronically reduced in PCD.
This is notable because nitric oxide production is upregulated in the respiratory epithelium
during infection. Therefore, it would be expected for an individual with chronic lung infections
to have elevated nitric oxide levels. If the levels are actually reduced, it is a sign that the patient
may have PCD. Chest x-rays may also be used to diagnose PCD [5].
The major challenges for patients with PCD include maintaining air way clearance, and
living with chronic upper and lower respiratory infections and chronic otitis media. Currently,
efforts are focused in treatments that slow the progression of the disease and help manage
symptoms. In order to monitor airway health, sputum cultures may be studied, and pulmonary
function tests, imaging, and bronchoscopies may be performed. These procedures may be done
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during a period of patient health to provide a “baseline” for later comparison. It is recommended
that routine sputum cultures are taken every six to twelve months, as well as during infection.
Pulmonary function tests have been historically used for patients with cystic fibrosis, asthma,
and chronic obstructive pulmonary disease. Studies are not clear on the value of pulmonary
function tests in patients with PCD, but it is still recommended patients have these tests every
three to six months. Baseline CT scans are important when looking for structural changes of the
lungs, such as the presence and progression of bronchiectasis. CT scans should be limited,
however, due to the radiation exposure. X-rays can also be useful when looking for pneumonia,
but it is more difficult to see structural changes, like bronchiectasis, on an x-ray. Bronchoscopy
allows for the physician to look directly into the passageways of the patients’ lungs, as well as
for the removal of mucus plugs or collecting tissue samples [5].
The most important thing for patients with PCD to do is to maintain airway clearance.
This helps preserve lung function, as well as prevent future infections. This can be done through
chest physiotherapy, vest therapy, acapella, flutter, or quake devices, mucus-thinning drugs,
bronchodilators, antibiotics and steroids. Chest physiotherapy and vest therapy are also used for
cystic fibrosis patients and they both work to physically loosen and move mucus secretions out
of the lungs and the airway. Acapella, flutter, and quake devices are positive expiratory pressure
devices, and help open up the airways, and in some cases vibrate the airways, in order to help the
patient cough mucus up an out of the respiratory system. Physical exercise also helps to open up
the airways and move mucus out of the lungs. Mucus thinning drugs help thin secretions in order
to make them easier to remove. Bronchodilators act to open and relax the airways, which helps to
move mucus out. Antibiotics and steroids can be used on a case-by-case basis to treat infection,
or as a preventative measure. Myringotomy tubes and hearing aids may also be necessary when
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chronic otitis media is present. Usually a combination of these physical and pharmaceutical
treatments is used to treat PCD [5].
Further research into the mechanism and treatment of PCD is supported by NIDsponsored Genetic Disorders of Mucociliary Clearance Consortium (CGMCC). The clinical
studies available are focused on understanding PCD rather than trying gene therapies. Currently,
clinical studies include comparing the inflammatory and microbiologic marker in sputum in
cystic fibrosis and PCD patients, studying the long-term lung function and disease progression in
children with early onset PCD, studying pathogens of PCD lung disease, and studying
dyskinesia, heterotaxy, and congenital heart disease [5]. Advocacy groups for patients with PCD
include the PCD Foundation [5] in North America and the PCD Family Support Group [8] in the
United Kingdom.
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PARKINSON’S DISEASE

Parkinson’s disease (PD) is a nervous system progressive disorder due to basal
ganglia degeneration and a decrease of dopamine [1]. PD is the second most frequent
neuro-degenerative disease behind Alzheimer’s disease, since it occurs more than 1% after
the age of 65 years [2]. There are many similarities and differences between these two
diseases, which will be covered later. PD is found in 1 million people in the US, while
60,000 people are diagnosed every year (US) and 4 million people worldwide [3]. The
demographic breakdown of the disease is as follows: PD occurs in about 1-2% of people at
age 60, 1 million in the US, and 4 million worldwide [3]; PD affects 1.7% of the Chinese
population [4]; 60,000 people get diagnosed every year in the US with PD [3]. It is inherited
and usually has two possible ways of inheritance. PD follows an autosomal dominant or
autosomal recessive inheritance pattern, depending on what gene(s) are affected [2]. So,
with the frequency of this disease, what causes PD?
James Parkinson discovered the disease in 1817 [1]. Parkinson’s relies on the
mechanisms and pathways of neurotransmitters. The neurotransmitter dopamine is
defected or at abnormal levels in a patient that suffers form PD. Torquato Torqauti first
isolated dopamine in 1910 [1]. The discovery of the disease coupled with the discovery of
neurotransmitters, especially dopamine greatly helped the further studies on PD and how
it works. The discovery of Neurotransmitters paved the way for further PD studies.
PD is often caused by genetic predisposition and exposure to certain toxins such as
chronic exposure to herbicides and pesticides may cause mutations in PD causing genes
[5]. These chemicals cause a disruption in genes by entering the genome. These genes code

for proteins that produce neurotransmitters. The brain ages slow and progresses slowly,
which will result in defective cognitive, memory, and motor functions, so aging is a major
factor for PD [6]. During aging, increases in metabolic or oxidative stress can lead to
neuronal defects and cell death [6].
Dopamine is affected in patients that suffer from PD. This is due to defects in genes
where proteins cannot produce enough dopamine. A major effect of PD is that it leads to a
loss of neural transmitters, which ultimately causes loss of motor control. Parkinson’s
disease (PD) mainly affects middle aged or elderly people [1]. This is due to “wear and tear”
on the body; PD can arise in all ages, however this is usually rare. Common Symptoms of PD
include tremor, dyskinesia, rigid muscles, as well as less accurate movement or muscles [3].
The disease is progressive, is often times not fatal but PD gets worse over time [3]. The
saying with PD is “you will die with Parkinson’s, not from it [3]”. Essentially PD does not
harm your organs just the response of the nervous system and it’s ability to send
neurotransmitters. There are medical options that help control your body by helping the
body cope with the defect, but as of now PD has no cure. A big foundation to finding a cure
is the Michael J. Fox foundation. He is a celebrity that suffers from PD and he greatly
supports the research to help patients. The National Institute of Neurological Disorders and
Stroke (NINDS) is also researching new cures and coping mechanisms for PD. What genes
or mutations are these research institutes looking at?
The first identified mutation in PD was a missense mutation of A53T in alpha
synuclein gene [7]. PD commonly results from a mutation in LRRK2, PARK2, PINK1, PARK7
and the SNCA gene [3]. The most common genes affected are PARK1, PARK2 and PARK7
genes [3]. The gene PARK1 associated with PD was first linked to PD in 1995 [5]. PARK1 is

located on chromosome 4 and codes for alpha synuclein [5]. PARK 2 is located on
chromosome 6 and codes for the protein parkin [5]. PARK7 is found on chromosome 1 and
codes for protein deglycase or DJ-1 [5]. This finding led to other studies to see how gene
defects leads to defective proteins such as parkin and how it decreases dopamine, which is
needed for motor skills.
Although there are mutations in some genes, a person with PD does not have a
different karyotype than a normal person [5]. A patient with PD will have 23 chromosomes,
however, it may be missing parts or segments of chromosomes, some could be noticeable,
whereas some are not. Gross chromosomal rearrangements may also lead to deletions or
defective genes that can cause PD. Mutations in the PARK2 and PARK7 genes are the most
frequent mutations for people with PD [5]. PARK2 encodes parkin, which is found in the
mitochondria [5]. Parkin helps degrade unneeded proteins by tagging proteins that are
damaged or in excess and help maintain mitochondria [5]. Parkin is expressed in the brain
or substantia nigra [5]. Parkin is a vital protein coded by the PARK genes. PARK7 encodes a
protein of the peptidase C56 family [5]. PARK mutations occur worldwide in diverse ethnic
groups [5].

There are many mutations that lead to a defect in PARK genes. PD causing genes
such as PARK2 could be deleted, duplicated or contain a mutation that codes for a different
amino acid (missense) [3]. A different coding sequence leads to defective genes and
proteins that affect the nervous system and the cells that make up this system. A mutation
will kill cells which lead to no dopamine production. This leads to a severe decrease in
Dopamine.

The main cells affected are neurons and the nervous system, which cause a defect in
the ubiquitin-proteasome system as well as a loss of function of parkin that cannot control
the release of dopamine, which is needed for control of muscles [5]. Parkin is a 46 amino
acid long protein located at the PARK 2 locus on the long arm of chromosome six [8]. Parkin
functions as an ubiquitin ligase that will attach ubiquitin molecules to wrongly folded
proteins to flag them so they can be processed by the proteasome [8]. Parkin targets
damaged proteins and degrades them to regulate the release of dopamine [5]. Parkin is
found in the ubiquitin-proteasome pathway that degrades proteins, and without this
function it is lethal to cells [5]. Parkin kills damaged cells and is how the body reacts to the
damaged cells. Therefore if parkin cannot degrade defective proteins, the cells will have
degraded proteins that will not be able to produce proteins, which ultimately leads to cell
death. PD patients are able to survive because they still produce some dopamine which
allows them to move, however it may be uncontrollable.

Mutations in PARK2 lead to degradation and cell death of the substantia nigra [5].
Nerve cells in this region produce dopamine, and this tissue death leads to an inability to
produce dopamine [9]. Nerve cells produce dopamine by signaling molecules at junction
gap receptors [9]. These receptors produce action potentials that release dopamine [9].
Loss of PARKIN function leads to abnormal mitochondrial structure and function [10].
Mitochondria functions in energy production and is vital to powering protein productions
that are used in all cells [10]. Dopamine relays messages that control body movement, and
a lack of dopamine severely hurts this ability [1]. The actual phenotype depends on what
gene is affected in one’s genome. Different mutations can lead to different symptoms and

defective proteins based on what gene is affected [8]. Heterozygous patients with PD
experience less sever symptoms than those with homozygous mutations of PD genes [8].
The neurons cannot create action potentials to stimulate the nervous system to control
motor movements. The most noticeable phenotype is uncontrollable shaking and posture
instability due to loss of motor skills. Another symptom is the reduced ability to swallow
since neurons power muscles needed to swallow. Dopamine is a very important
physiological role controlled by parkin and is conserved in mammalian genetics [1]. Since
this gene is vital to mammals, various animal models can look at genes at a more in depth
level with manipulation and other variables.

In order to research this disease mouse models are frequently used to study PD
because of the similarity of PD with other neuro-degenerative diseases such as Alzheimer’s
[3]. It is crucial to see the differences between the two diseases. Alzheimer’s has very
similar symptoms because it is a neurodegenerative disease and is a result of the aging
process and accumulation of mutations [8]. Alzheimer’s is a disease that results from gene
defects that are important in a different part of the brain, the hippocampus and the
entorhinal cortex [8]. Dopamine is not able to transfer messages from this part of the brain,
which often results in memory loss and not motor loss, due to the nature of the
hippocampus [1]. Since these two diseases are very correlated, different animal models are
used to study PD. Mice are widely used as an animal model for researching PD [6]. To do
this, mice are injected with toxic chemicals that cause loss of function in PD causing genes
such as the SNpc region [6]. Motor function decreases in mice as they age [6]. Age
associates genes that most affected mice can be used to look at in humans with PD [6]. Age

associated genes are prone to mutations because they have an accumulation of mutations
over time, not because of the age itself. From the in depth study on mice models, newer
treatments could arise to help patients cope with PD. Mice are also used because in mice
the substantia nigra also degenerates due to mutations in PARK2 and PARK7 [1]. The
model is that mice will get injected to decrease dopamine production and degrade the
substantia nigra so that it resembles a human that suffers from PD.

The diagnostic test used to see if someone as PD is a neurological examination
performed by the doctor as well as medical history examination [2]. Family history and
family trees is a very good indicator of PD. It can give you a probability of inheriting the
disease and can help determine if your kids are at risk as well. This is vital since it has
inheritance patterns as stated previously. This is commonly used to diagnose people to see
if they have PD or not. PD can be predicted to see a child’s risk or can be used to see a
patient’s likelihood of contracting the disease. Through medical history examination and a
neurological test, PD can be detected [8]. Stem cells in embryos can be directed to make
more dopamine, which can help avoid PD before birth [8]. However this has to be done at a
very early age, and even in the womb, but sometimes it is hard to detect PD in a baby
before birth. Most of the stem cell research is proposed and is not being used because of the
ethical dilemma. There are several treatments and drugs used to help cope with PD.
Carbidopa-levodopa is the most effective medication since it is a natural chemical
that can enter the brain since it can pass through the blood brain barrier [5]. This drug is
effective because it can be converted to dopamine to help increase dopamine levels in the
body [5]. By having a drug that can be turned into dopamine will greatly help. Another

effective drug is called a MAO-B inhibitor. MAO-B inhibitors help prevent the breakdown of
the brain dopamine by inhibiting enzyme monoamine oxidase B, which metabolizes
dopamine [5]. This will allow dopamine to buildup and not be degraded, which can help
increase levels of dopamine in the brain. Another great treatment, although controversial is
Deep Brain Stimulation (DBS) can help stimulate parts of the brain that are used to control
motor movement and help activate parts of the brain that are not frequently activated due
to defective genes [11]. It is controversial because many people think deep brain
stimulation can be harmful to normal individuals. However, it is being tested further and
will hopefully improve life of those suffering with PD.

S
Parkinson’s Disease has no cure and most of the problems are due to defective genes
that cannot code for the parkin protein that get’s rid of damaged proteins that make
dopamine. Most treatments attack the problem of low levels of dopamine in the body and
find different ways to increase dopamine in the brain. Medical treatments to help control
muscles by dopaminergic therapy can help improve quality of life [8]. Dopaminergic
therapy is adding in dopamine neurotransmitters to the right tissues in the brain. Since
there are no cures, therapy to help patients cope with PD can help patients live a longer life.
This is crucial because there are millions of people in the US and around the world that
suffer from PD.
Future studies and advancement in technology to identify more pathways
associated with PD will greatly improve the chances of curing PD. As for now, only
treatments can help cope with PD. If further studies can find how to fix gene defects so that
they can produce the correct amino acid sequence in order to produce parkin proteins,

dopamine levels will rise. However, the complex nature of the pathways coupled with the
genome will create big challenges in order to cure this disease.
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Introduction to Werner Syndrome
Werner Syndrome (WS) is one of the segmental progeroid syndromes
diseases manifesting accelerated aging that affect multiple organs and tissues
(Martin and Oshima 2000). The disease is named after the German scientist, Otto
Werner who discovered and identified the syndrome from four siblings who had the
symptom of premature aging in 1904. WS was discovered to result from rare
autosomal recessive alleles of mutations at the WRN gene on chromosome 8, which
encodes the RecQ DNA helicase (Yu et al. 1996). There is also the known chance that
the disease mutations tend to run in families. Both sexes can be affected and also
with even higher change between brother and sisters from the same carrier or
infected parents since (Takemoto et al. 2013).
The global incidence rate of Werner Syndrome disease is less than 1 in
100,000 live births (Hasty et al. 2003). However, in Japan and Sardinia, they tend to
have a higher rate of 1 in 20,000-40,000 and 1in 50,000, respectively (Masala et al.
2007). The approximate Lifespan for these WS patients is around 50 years old
globally (Hasty et al. 2003), 47-48 in Japan, and 54 years in Sardinia (Masala et al.
2007).
In between 2009-2011, a nationwide epidemiology study in Japan was
conducted with 6921 surveys sent to hospitals and clinics experienced with WS
(Takemoto et al. 2013). They found that more than 90% incidence were recorded as
cardinal signs, symptoms or sign of heart disease, with many criteria. WS patients
are usually observed as having a normal phenotype early in life until they reach the
late 20s to early 30s, where the first symptoms begin. The first clinical sign of WS is

a lack of early adolescent growth spurt, which leads to short stature, loss of body
weight, skin atrophy, Loss of regional subcutaneous fat, and graying of hair. The loss
of fat is usually related to the ulcerations in the regions such as elbows and ankles.
In addition, the limb ulcers are influenced by neuropathy and vascular insufficiency,
which may require amputation later on. Others symptoms include type 2 diabetes
mellitus, osteoporosis, bilateral ocular cataracts, several forms of arteriosclerosis,
alopecia, malignancies, telangiectasia, and peripheral neuropathy (Leistritz et al.
2007).
The severity of patients with Werner syndromes can be explained by the
different functions of WRN gene, which plays a very important role in DNA
replication, repair, and recombination. One WS characteristic is increasing genomic
instability due to many mutations, which likely is the cause of cancer and many
more disease that normally have a late onset in unaffected individuals (Crabbe et al.
2007). However, the common cause of death among WS patients is usually related to
myocardial infarction or cancers (Huang et al. 2006).

Genetic component of the disease
After the discovery of the Werner Syndrome in 1904 as part of Otto Werner’s
dissertation research in Germany, many researchers and geneticists have been both
accidently and directly identified the WRN gene and its relative functions leading to
the diseases and the different phenotypes between affected individuals. Later in
1934 to 1941, two scientists from New York, Oppenheimer and Kugel, named the
term “Werner Syndrome” igniting the popularity on this research topic. However, it

was not until 1981 that the real genetic component, the WRN gene on chromosome
8, was discovered for the first time after centuries of study by many geneticists
(Goto 2004).
Werner Syndrome is caused by mutation of the WRN gene on chromosome 8.
The approximate size of this gene is 250 kb, containing about 35 exons, 34 of which
are protein coding (Yu et al. 1996). The WRN protein is a 180-kb multifunctional
nuclear protein that belongs to the RecQ family of helicases (Grey et al. 1997).
Among WS affected individuals, their karyotypes usually differ from the normal
population karyotype due to the abnormal expression of the mutated WRN gene.
This difference in WRN expression can cause the loss of a telomere at the end of
chromosome, which can consequently create fusions between chromosomes or
sister chromatids, reciprocal translocations, leading to a change in karyotype
(Crabbe et al. 2007).
One main role of WRN requires an N-terminal domain that codes for
exonuclease activity (Huang et al. 1998) and also where a domain for single strandDNA annealing activity is happened to be located (Muftuoglu et al. 2008). Within
this N-terminal domain with single strand-DNA annealing activity of helicase and
exonuclease, the main wild type functions are thought to be related to DNA repair,
DNA recombination, and DNA replication of the chromosome (Brosh et al. 2006;
Friedrich et al. 2010). Furthermore, the proteins produced from WRN gene are also
involved in telomere maintenance (Crabbe et al. 2007).
The mutations in WRN create malfunction or absence of the proteins. There
are more than 70 WRN gene mutations found in human, such as nonsense

mutations, missense mutation, substitutions at splice junction, and
insertion/deletions have been showed in WS patients (Aydogan et al. 2015). These
different in mutations however are possible to cause some slightly different in the
disease symptom.

Molecular biology and biochemistry of the disease
Study of Laure Crabbe in 2006 has proven that the cause of genomic
instability in WS cells has the direct effect on the telomere dysfunction. Since human
linear chromosomes undergo terminal sequence loss during cell replication and
eventually the telomere become critically short (Crabbe et al. 2007). This is one
important concept because one of telomere main function is to maintain the
chromosome stability. Abnormalities phenotype or shortening of the telomere
region on the chromosome may eventually leads to complication like chromosomal
breakage and translocation (Friedrich et al. 2010).
The phenotype of the disease at the cellular level is usually observed by
visualizing the telomere region, repeated sequences at both ends of the
chromosomes. Since the mutation in the WRN gene is proven to have the direct
affect on shortening the telomere on the chromosomes, different phenotypes at the
cellular may be able to identify. Among these differences, the chromosome breakage
and translocation of chromosomes, rejoined region of two different chromosomes
may be able to visualized in the karyotype as well (Friedrich et al. 2010).
There are many cell types and tissues involved with the Werner Syndrome.
Because of the mutations within the WRN gene that is normally function as the

growing stimulator and telomere maintaining mechanism. Mutations in WRN gene
then is possible to interrupt the normal function of the gene, causing the change in
different types of protein productions, which leads to the abnormal development of
the effected cells and tissues. These cells and tissues abnormalities tend to manifest
the old person age phenotype, which again leads from the malfunction of the
proteins produced from the mutant WRN gene. Many obvious examples are greying
of hair color from the effected hair cells, and early ulcerations of the skin from the
effected skin cells and tissues.
The WRN proteins involve with helicase and exonuclease activity (Yu et al.
1996). The main function of the Werner protein produced from WRN gene is
required for cell growth and proliferation (Li et al. 2014). The cellular pathways
involved WRN protein that has been studied implied that it monitor and maintain
DNA integrity (Rossi et al. 2010). Other known tasks of this protein are maintenance
and DNA repair. The protein also supports the process of DNA replication as a
preparation for cell division.
Mutations in the WRN gene lead to the production of an abnormally short
and nonfunctional WRN protein. This protein is also believed to broken down very
easy and unable to transport to the cell’s nucleus, where it normally interact with
DNA. However, we are not yet fully understood how the mutations in WRN gene
lead to WS signs and symptoms. One assumption would be that cells with mutant
WRN protein tend to divide more slowly and stop dividing earlier compared to the
normal cells, which affect growing process of the individuals carrying the disease. In
addition, the nonfunctional WRN protein also allows the DNA damage to increase,

which disrupts the normal cells functions and the cells will usually be associated
with diseases, cancers (Aggarwal et al. 2011).
The WRN gene also found to be highly conserved within mice population.
Many scientists discovered known homolog of the proteins in mice and also the
mutation is in a conserved in the region of WRN gene in mice (Li et al. 2014). The
study shows that the mutations in the mouse WRN gene also cause the early death
and many complication age-related disorders, similarly to human.

Clinical aspects and organismal phenotypes
The most popular diagnostic test for Werner is the Next-generation
sequencing analysis of the WRN gene, looking for the WRN mutations, especially
Frame shift mutation (Yang et al. 2015). However, there are different levels of the
diagnostic options. For example, the level of biochemical genetic test likes protein
analysis. Another level is molecular genetics tests, which is for mutations like
deletion/duplication analysis, and sequencing analysis of the entire coding region is
also fall into this group of diagnostic.
Variability in phenotype of WS is highly a penetrant gene at least for disease
like cancer (Yang et al. 2015). Many individuals could become a carrier that the
disease alleles are penetrant. However, WS phenotype could be extremely
expressivity when the individuals carry two mutant alleles in the WRN gene, which
lead to the manifestation of the normal aging-related diseases.
Role of the genetic element in other disease like cancer is very well studying
right now. According to the Liu Yang study in 2015 identified that novel WRN

frameshift mutation was identified in three cancer patients and one in the youngest
unaffected daughter, carrier. In the other disease involving cardinal muscle is also
highly possible to be affected by the genetic element abnormalities of the WS.

Issues for the affected individual and treatments prospects
To detect the disease early on, the family members of the infected individual
with the Werner Syndrome are required to have the sequencing analysis tested for
the mutant WRN gene. The couples consulting for sequencing analysis test before
having children can also be performed to avoid having the infected children with the
WS.
Many treatments or technics for several symptoms of Werner Syndrome
have found to be very effective. For example, treatment for skin ulcers with
standard or novel techniques is proven to help reducing the causative of the
symptom (Yeong & Yang 2004). Another treatment option for skin ulcers is the
Bosentan, digital ulcers treatment, which it is proven to be very effective in people
with Werner syndrome having complication with the skin ulcers (Matucci-Cerinic et
al 2011). Scanning for type 2 diabetes mellitus and consulting with the physician for
controlling the symptom may also help. Acceptable results have been reported with
use of pioglitazone to treat for the insulin resistance in-patient with WS (Imano et al
1997). Regular treatment for malignancies in WS is also one of the options to treat
for tumors and cancer related symptoms.
The major challenges faced by individuals with the disease is always
involving maintaining the healthy conditions, since many abnormalities both

genotype and phenotype of the infected individuals are constantly increase
overtime. Since it is very difficult to treat or reduce the symptoms of the WS.
Individuals could prevent secondary complications by adjusting their Lifestyle. For
example, smoking avoidance, regular exercise, and weight control to reduce
atherosclerosis risk are extremely recommended by the physicians. Excellent skin
care, trauma avoidance, and examination to treat problems early may also help.
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Sickle Cell Disease
The foundation of sickle cell disease is built on the β-globin variant found on the short
arm of chromosome 11 [1]. Hemoglobin composition changes throughout development. Fetal
hemoglobin (HbF) is composed of two α-globin proteins and two γ-globin protein [2]. Adult
hemoglobin (HbA) will have two β-globin proteins adjoining two α-globin proteins [1,2]. At
birth, the infant has roughly 80% HbF and 20% HbA. This transition is complete around 6
months with HbA being the homozygous dominant, or wild-type [2]. Deformity of red blood
cells into a crescent-shape is due to variation in the β-globin amino acid chain. At position 6,
valine replaces glutamic acid causing the polymerization of deoxy sickle hemoglobin (HbS).
This leads to the formation of long protein chains causing complications such as vasoocclusion
and hemolytic anemia [1,3].
With this disease, those that are homozygous for wild-type alleles (HbA) are completely
unaffected while those that are homozygous recessive typically suffer from anemic disorders.
Recessive homozygosity can result from two copies of HbS or one copy of HbS and another βglobin variant such as HbC, HbE, and HbD [1,3]. In addition, recessive variations include α
thalassemia and β thalassemia [3]. Thalassemia is a Greek word referring to autosomal
inheritance of blood disorders. Alpha-thalassemia results from a mutation on chromosome 16
causing a deficiency in α-globin proteins which in turn produces excess β-globin proteins.
Because this mutation occurs on different chromosome, another gene separate from the one for
sickle cell disease, it does not affect the genotype. However, it has shown to have phenotypic
implications [4]. Beta-thalassemia is caused by the deficiency of β-globin proteins leading to
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additional α-proteins, and the mutation is found on chromosome 11 [2]. Beta-thalassemia
mutations are also allelic variations of the globin genes that can be passed on to the offspring [1].
There are two types of β-thalassemia, β0 and β+. Both cause a reduction in β-globin; however, β0
causes complete absence of hemoglobin synthesis leaving those individuals with phenotype
produced by the other copy present [2]. If they are HbS/ β0 thalassemia, they would be
phenotypically similar to those that are HbS/HbS. Most patients with β+ have shown milder
forms of the disease as it still produces some normal hemoglobin [3].
Heterozygous individuals are often unaffected by the downfalls of the disease, but
maintain an additional beneficial aspect not seen in wild-type individuals. Heterozygosity has
benefits through conferring resistance to malaria without the harmful side effects [3]. This is due
to production of HbS from only one allele. Because the other allele for heterozygotes (HbA)
produces normal hemoglobin, the symptoms such as vasooclusion and anemia to not develop, yet
these individuals are still protected from malaria [1,3]. Resistance to human malaria was first
genetically demonstrated in 1954 when sickle-cell heterozygous individuals responded
significantly less to Plasmodium falciparum infections [4]. Continued research including
genome-wide associations has identified the HBB locus to be the source of this resistance.
Populations living near the coasts Kenya and Lake Victoria have higher frequencies of sicklecell heterozygotes than those in the highlands where malaria is uncommonly transmitted [4].
This follows the concept of positive selection. In populations living in areas where malaria is
high, there has been a genetic shift toward an increase in heterozygotes because these individuals
show greater fitness. This explains the absence of a selective sweep involving the removal of the
sickle cell allele. This is supported by studies of P. falciparum transmission into individuals,
(HbA/HbS, HbA/HbA, HbS/HbS). Sickle-cell heterozygotes (HbA/HbS) survive better than
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those with normal hemoglobin, homozygous dominant (HbA/HbA) [4]. Homozygous recessive
(HbS/HbS) have the highest mortality rate due to the symptoms of the deformed red blood cells.
The carrier form of HbS has been found to be negatively associated with all potentially
lethal forms of falciparum malaria; however, HbC and α-thalassemia have not shown protection
against malaria and are limited to conditions of cerebral malaria and severe anemia, respectively
[4]. HbS red blood cells are assumed to have specific physical or biochemical properties which
affect the invasion, growth, and development of P. falciparum parasites. [5].When such cells
undergo in vitro, parasite-infected HbA/HbS red blood cells also tend to sickle. In Sudan, the
immune system’s recognition of P. falciparum infected red blood cells was greater in children in
addition to the up-regulation of malaria-specific cell-mediated immune responses [6]. A variety
of studies have shown that malaria resistance is enhanced in younger patients. At first it was
thought that the resistance is innate in that the mechanisms of resistance work in the early stages
of diseases or infections. This precedes the immune response that adapts in order to take over
after the course of a few days [4]. However, it is suggested that if malaria protection by HbS in
HbA/HbS individuals was an innate resistance, it should be independent of age which is not
consistent with the findings of the study in Sudan [4].
Chronic intravascular hyper-hemolysis has been found to characterize a new, specific
type of sickle cell anemia subphenotype. Identification of this may highlight the finding of
disease modifying factors in order to develop new therapies [7]. This novel subphenotype has
shown signs of reduced vasoocclusive pain but sooner mortality rates as well as increased
reticulocytosis which is a physiological response to extravascular and intravascular red blood cell
destruction [7]. Lactic dehydrogenase (LDH) can be distributed in order to measure hemolysis
levels and would be a possible identifier of this subphenotype. Association of lower HbF levels
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has been found in relation to decreased α thalassemia, a genetic factor that has been found to
reduce anemia and hemolysis [7]. This subphenotype has illustrated increased severity as high
levels of HbF are associated with reduced pain, acute chest pain, and mortality as HbF has the
ability to inhibit polyermization of HbS. In turn, this decreased vasoocclusion and hemolysis [7].
Another common symptom of sickle disease is hypoxia which is especially common in
children. This has been associated with increased severity of the disease characterized by low
levels of HbF resulting in cases of abnormal lung function [8]. This can only partially be
explained by anemia as one study found that it represented only 5% of arterial oxygen
desaturation. [8]. One factor that potentially explains the diminished affinity of HbS for oxygen
is the increased concentration of erythrocyte 2,3-biphosphoglycerate. This decreased the life
span of an erythrocyte via apoptosis due to increased Ca (2+) activity [9].
A major cause of death in patients with sickle cell disease may be pulmonary
hypertension. Frequent reports of sudden death in adults with sickle cell disease in the absence of
coronary artery disease has been associated with hemolysis [8]. Despite having lower
pulmonary-artery pressures and higher cardiac outputs than patients with primary pulmonary
hypertension, patients with sickle cell disease and pulmonary hypertension had a significantly
higher mortality rate than did patients with sickle cell disease who did not have pulmonary
hypertension. [10] Chronic hemolysis releases hemoglobin into plasma which can catalyze the
reaction between oxygen and nitrogen resulting in acute and chronic pulmonary vasoconstriction
by increasing the transcriptional up-regulation of adhesive molecules [10].
Echocardiography can be used to identify at-risk patients through the noninvasive
measurement of tricuspid regurgitant jet velocity. This prognostic tool can provide additional
data alongside the transcranial carotid Doppler flow-velocity assessment, which is used to
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predict the risk of stroke in children with sickle cell disease. [10] Research has found
hydroxyurea increases levels of HbF, therefore, decreasing morbidity from vasoocclusive
complications in patients [11]. A more extreme form of treatment is the transplantation of
hematopoietic stem cells. Unfortunately, patients with hemoglobin-based diseases, such as sickle
cell disease, have been found to have transplant rejection more frequently than other blood
disorders including aplastic anemia, severe combined immune deficiency, and malignant
conditions [12]. The common downfall results from iron overload leading to liver disease.
Patients with β-thalassemia who undergo transplantation early have seen a higher success rate
[12].
It is vital to continue research on not only treatments, but the fundamental aspects of the
disease. By understanding the biochemical breakdown of sickle cell disease, therapeutic options
can be enhanced in addition to the potential for a cure. The variations discovered thus far have
demonstrated the complexity of the disease as well as an opportunity to work from a genetic
basis to a physiological understanding. Sickle-cell disease still contains many unknowns and
maintains an unpredictable course; however the benefits of heterozygosity provide justification
of continued research.
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Abstract
Cystic fibrosis is an extensively studied disorder caused by a monogenic inherited
disease. This disease results from mutation in the cystic fibrosis transmembrane regulator gene.
CFTR codes for a complex protein that is vital to normal functioning. This research paper
compiles information over the disorder and examines life with the disease from a clinical,
molecular, and genetic viewpoint. The method for writing included looking over various
scientific articles.

Introduction
Cystic fibrosis is a fairly common autosomal recessive disorder in European
populations. It is characterized by thick and sticky fluid in the cells that produce mucus, sweat,
and digestive juices. Symptoms include pain in the abdomen, burning sensation in the chest,
coughing, wheezing, and gastrointestinal problems. Patients with CF will have salty-tasting skin,
frequent lung infections, poor growth and weight gain, frequent greasy, bulky stool or problems
with bowel movements, and even infertility in males. The secretions of the cell aren’t thin and
slippery as in normal people, so instead of acting as a lubricant, the secretions plug up tubes,
ducts, and passageways. The buildup of mucus traps bacteria, which increases the risk for
infection. This leads to lung damage and eventually respiratory failure. The mucus buildup
prevents the release of digestive enzymes from the pancreas, making the break down and
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absorbance of food difficult. The disorder requires daily attention but those diagnosed with it can
live fairly normal lives with an average life expectancy in the 20s and 30s.
Cystic fibrosis has a prevalence of 1 in 2500 European populations. Cystic fibrosis
occurs in roughly 1 in 2000 births in northern European population (Zemanick et al. 2010).
According to the National Institute of Health approximately 30,000 people in the US are living
with cystic fibrosis. Every year there are 1,000 new cases. The majority of people with CF are
diagnosed by two years old.
It is speculated that cystic fibrosis has been around since 3,000 BC (Busch 1989).
Although the first paper about CF wasn’t published until 1938. Dorothy Hansine Andersen
published “Cystic Fibrosis of the Pancreas and its Relation to Celiac Disease: A clinical and
Pathological Study,” in the American Journal of Disease of Children (Andersen 2009). It is a
complex disorder and the symptoms and severity of the symptoms vary from case to case.

Genetic Component
People with cystic fibrosis have inherited two copies of the defective gene. Each copy
must come from a parent meaning that both parents must be carriers of at least one copy of the
gene for their offspring to inherit the disease. Carriers of the disease only have one copy and do
not show any of the symptoms.
In 1989 cystic fibrosis was found to be caused by mutations in a previously unstudied
gene. The novel cystic fibrosis transmembrane regulator (CFTR) gene was predicted to regulate
transmembrane conductance, and was subsequently shown to function as a channel that allows
chloride ions to pass through the cell membrane. A great deal was discovered about aspects of
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CFTR biology that would inform diverse fields such as protein trafficking and membrane
transport. According to the Cystic Fibrosis Mutation Database there are currently 1,991 CFTR
mutations. The most common mutation, F508 is a deletion of three nucleotides. This results in a
loss of the amino acid phenylalanine (F) at the 508th position on the protein (Griesenbach et al.,
2016). The F508 deletion on chromosome 7 has been found in approximately 70% of gene
carriers for cystic fibrosis and provides an opportunity to offer detection of carrier state both to
members of the general populations and to members of families whom cystic fibrosis has been
diagnosed (Knight et al., 1990). This mutation alone, accounts for two-thirds of the mutations in
cystic fibrosis worldwide.
The different mutations that cause CF can be divided into four classes. This first class of
mutations affect protein production and include the nonsense mutation G542X. There are
mutations throughout the CFTR gene that produce premature termination signals because of
splice site abnormalities, frameshifts due to insertions or deletions, or nonsense mutations (Tsui,
1992). The second class of mutations affect processing, where proteins fail to progress through
the biosynthetic pathway. This includes the most common mutation, deletion of phenylalanine at
residue 508 (F508). The third class is defined by problems in protein regulation. An example of
this is the G551D mutation. Although missense mutations have been reported in the regulatory
domain, there appear to be fewer mutations than in other parts of the protein (Welsh and Smith,
1993). The fourth class of mutations causing CF result from defective conducting, where the rate
of ion flow through a single open channel is reduced. The missense mutation R117H in the first
membrane-spanning domain falls into this class.
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The product of the CFTR gene is a chloride ion channel important in creating sweat,
digestive juices, and mucus. When there is a mutation in this gene it prevents normal secretion
from the chloride ion channels. The absence of this gene function is what cause the thick mucus
in patients with CF.
The CFTR gene was cloned and identified to produce a protein, the CFTR protein that
regulates chlorine ion channels. This seemed to be the cause of the thickening of mucus. It was
believed that lack of this gene is what caused the hyper-mucosity. Further research has found that
the mechanism for this is complex and varies from organ to organ with lungs being the most
complex. It is now hypothesized that it is actually a gene downstream to this gene that causes the
symptoms that we see in the people with the disease. The mucus hyper production that typifies
CF does not appear to be a direct cause of a defective CFTR but, rather, to be a downstream
consequence. In organs like the lung, up-regulation of mucin gene expression by inflammation
results from chronic infection; however, in other instances and organs, the inflammation may
have a non-infectious origin (Kreda, 2016). Since there are many variations of the disease it is
hard to pinpoint the exact cause and it may not be the same for all mutations.

Molecular Biology and Biochemistry of disease
Mutations in the CFTR gene affect multiple organs, including the intestine, sweat glands,
pancreas and the reproductive system, but cystic fibrosis lung disease causes most morbidity and
leads to premature mortality in cystic fibrosis patients (Griesenbach et al., 2016). CF mostly
affects the epithelium cells of the lungs, pancreas, liver, and kidneys. The mutation causes either
loss of function or dysfunction. The reason that death from lung infection is so predominant is
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due to the dehydration of liquid on the surface of airways. This prevents ciliary action of the cells
that normally move mucous away. Another alternative is that the disorder causes inflammation in
the host. Patients with CF are susceptible to opportunistic bacteria, most notably Pseudomonas
aeruginosa (Zemanick et al. 2010). This theory that inflammation is what causes eventual lung
breakdown is less widely accepted. The role of CFTR expression in inflammatory cells such as
neutrophils, macrophages, and more recently T cells, has been widely, and so far, inconclusively
debated, but studies overall appear to suggest a potential defect in adaptive immune responses in
patients with CF, which may explain the exaggerated pulmonary inflammatory responses that
have been generally observed, an area that requires further studies (Griesenbach et al., 2015).
CFTR is found at the q31.2 locus of chromosome 7 (Zengerling, 1987). It is 230,000
base pairs long, and encodes for a protein that is 1,480 amino acids long. While there are
approximately 2,000 different alleles in the CFTR gene associated with the diseases, there is no
evidence that all these cause the disease phenotype. CF allele distribution varies by population. It
is hypothesized that having CF benefited from resistance to cholera and other causes of diarrhea.
That is heterozygous individuals would be less susceptible to cholera. The selection of the CF
mutation and its cellular consequences present evidence which suggests that resistance to cholera
may have been the environmental factor which selected CF heterozygotes over their ‘normal’
homozygote cohort (Rodman 1991). A study done by Patrick Sosnay at John Hopkins University
looked at genotype and phenotype data for 39,696 affected people in clinics and registries and
clinics in North America and Europe. In these individuals, 159 CFTR variants had an allele
frequency of 0.01%. These variants were evaluated for both clinical severity and functional
consequence, with 127 (80%) meeting both clinical and functional criteria consistent
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with disease. Assessment of disease penetrance in 2,188 fathers of individuals with cystic
fibrosis enabled assignment of 12 of the remaining 32 variants as neutral, whereas the other 20
variants remained of indeterminate effect (Sosnay et al., 2013). This study is significant because
it shows that there are a lot of different mutations in the CFTR gene that give rise to CF. Those
with a single working copy are carriers, but otherwise function normally. The most current
theory on how cellular defect can cause clinical effects is that defective ion transport leads to
dehydration in the airway epithelia, and therefore thickening mucus. Population based studies of
CF are becoming more popular, with 1.2 million people subjects in the US alone. Genetic testing
is highly recommended for people who are showing symptoms and for couples who might be
carriers for the gene.

Clinical aspects and organismal phenotype
Screening for CF includes testing for immunoreactive trypsinogen, then confirmation
through a scan for CFTR mutations. Most children are diagnosed by six months of age. Diabetes
is the most common non-pulmonary complication, but lung disease and infertility are also issues.
There is a wide variability in the disease and most treatments are tailored to the
individual. Most treatment options are aimed at reducing symptoms of the disease rather than the
cause of the disease. There are a variety of different therapies that patients can go through.
Airway clearance helps to get rid of thick mucus in the lungs. This therapy may require a
respiratory therapist. An inflatable vest vibrates the chest at high frequencies to help loosen and
thin mucus. Inhaled medicines can also aid in opening air passageways. A liquid medicine is
usually made into a mist or aerosol. The medicine is then inhaled via a nebulizer. Pancreatic

Page 7
enzyme supplement capsules can also be taken with every meal to help facilitate the absorption
of important nutrients. Antibiotics include Piperacillin, Azithromycin, Aztreonam,
Ciprofloxacin, and Tobramycin. All of these drugs are designed to treat bacterial infections.
Tobramycin is specially designed to treat lung infections.
CF is equally prevalent in males and females, but females have a slightly shorter life
expectancy. The reason for this is unknown but the gap is decreasing as healthcare becomes
better and more accessible. Similar “gender gaps” have been seen in asthma and COPD (chronic
obstructive pulmonary disease). Researchers have speculated that sex hormones play a role in
this gap. More research needs to be done as there are many factors affecting life span such as
exercise, nutrition, socioeconomics, and environment.
People suffering from CF are often given a special diet or a list of recommended foods.
This diet is high in fat and calories. Since the mucus is so thick in the intestines, it makes it hard
for nutrients like fats and vitamins to be absorbed. That is why teenagers suffering from this
disorder are usually short and underweight for their age. This also makes them more susceptible
to illness as their bodies can’t fight off infections very well. Consuming extra calories aids in
fighting off infections as well as keeping their lungs strong. Even if the patient isn’t feeling
hungry it is necessary to keep consuming food to fight off malnutrition. Just like anyone else
they need a well-balanced diet. It is recommended that they consume 2,900-4,500 calories per
day. Just like any other factor of the disease, everyone person has their own nutritional needs.
Patients are able to work with a CF nutritionist to develop a diet plan for weight gain.
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Issue for affected individuals and treatments
There is no cure for CF and it is a chronic illness. It puts a great deal of emotional stress on a
person as well as their family. People with CF need constant care, expensive medication, and are
more prone to depression or anxiety. The disorder is lifelong and also shortens the lifespan of the
patient. Those suffering from CF are more prone to depression only due to the amount of stress
they are under combined with the decrease in quality of life. Exercise can be beneficial to those
suffering because it releases endorphins as well as strengthening the lungs capacity. People with
CF shouldn’t smoke or it will increase their chances of lung disease. Despite requiring daily care,
CF doesn’t stop people from performing daily tasks such as working or going to school. Patients
are required to check in with a doctor every three months and the better treatment they receive
the longer lifespan they will have.
Treatment includes antibiotics, chest physiotherapy, and pancreatic enzyme replacement
for those with pancreatic insufficiency. Lung transplants are also an option. Gene therapy has
been explored as a potential cure for CF. It is focused around trying to put a functional copy of
the CFTR gene into affected cells. Gene transfer has been attempted multiple times, with
liposomes and viral vectors in animal models and in clinical trials. Unfortunately these methods
were inefficient. This is because very few of the cells take up the vector and express the gene.
Pulmonary gene therapy is especially difficult because the lung is a complex organ designed to
keep out foreign bacteria and viruses. Some gene therapy may not completely fix CFTR gene
function but even a little bit can improve lung disease. The discovery that even a slight
improvement in gene function can improve the disease has renewed interest in gene therapy as a
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form of treatment. Extensive antimicrobial treatment can be used to eradicate infections in the
lungs. Unfortunately this gives rise to resistant strains of bacteria.
The US food and Drug administration approved the first drug that targeted the cause of
cystic fibrosis in 2012. This drug, ivacaftor, helps to reopen chloride channels that are closed by
G551D mutation. According to the FDA website, two 48 week clinical studies were conducted
with 213 patients. In both studies, patients taking ivacaftor showed significant and sustained
improvement in lung function. Before 2012 most drugs were only administered to treat
symptoms of the disorder. The FDA approved the second drug to target the root cause of CF in
2015. These CFTR modulators are a breakthrough in treatment and have the potential to add
decades to the lives of CF patients.
The possibility of a lung transplant can improve the lives of patients. In this surgical
procedure the unhealthy lung is removed and replaced with a healthy one. A lung transplant
requires a lot of planning and is fairly expensive. Sometimes a transplant called living donor
lobar lung transplant is performed where only the lower lobe of the lung is transplanted. The
major risk of this procedure is rejection of the organ or infection. It is only recommended in
people who have extensive lung damage. It is important to note that the transplant does not cure
the problem of CF and the new lung will also be affected by the thickening of the mucus. That is
why this procedure is less common.

Conclusion
In some countries, newborns are screened for this disorder. The knowledge about the disease
is expanding and many new treatments have finished clinical testing and are being acclimated
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into mainstream treatment. Our understanding of cystic fibrosis pathophysiology and genetics is
constantly expanding and being refined, leading to improved management of the disease and
increased life expectancy in affected individuals (Griesenbach et al., 2016). There is still much
that is not known about CF such as what other modifier genes affect disease progression. There
are other challenges like adequate healthcare. Most drugs for CF are expensive and not everyone
can afford them. Even more important a lot of countries don’t have access to sufficient health
care. Developing drugs is a long and costly process. While scientists may be close to finding a
permanent cure, it will be years before the drug is put on the market. Current medicine has
greatly improved the quality of life for people living with CF. Hopefully patients will see a
breakthrough in treating the cause of the disease. Either way one thing is for certain, more
research needs to be done.
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